



2020

Korea Innovative **PHARMACEUTICAL** Company



Ministry of Health
and Welfare



This brochure illustrates a project promoted by Korean pharmaceutical companies and with support from the Korean government, to enter global markets. You'll meet the Korean pharmaceutical industry as a reliable partner for global collaboration.

Contents

02	Current Status of Korean Pharmaceutical Market
08	Introduction of Korean Innovative Pharmaceutical Company Certification System
10	Information of Korean Innovative Pharmaceutical Company
55	Supplement

Current Status of Korean Pharmaceutical Market

(Market size) Korean pharmaceutical market passed the \$21 billion mark in 2018. Its growth has been driven by leading Korean companies, which have been releasing new global drugs and achieving technology exports.

Pharmaceuticals exports have increased at a CAGR of 17.9% for the past five years (2014-2018), fueled especially by increases in Korean drugs entering into global markets.

Current status of Korean pharmaceutical market (unit: million dollar, %)

Category	2014	2015	2016	2017	2018	Year-on-year growth rate	CAGR ('14~'18)
Market size	18,396	16,963	18,712	19,508	21,004	7.70%	3.40%
Production	15,593	14,991	16,198	18,000	19,176	6.50%	5.30%
Exports	2,416	2,946	3,119	4,069	4,673	14.80%	17.90%
Imports	5,219	4,918	5,633	5,577	6,501	16.60%	5.60%
Trade balance	△2,803	△1,972	△2,514	△1,508	△1,828	△21.2%	△10.1%

* Source: Press release by the Ministry of Food and Drug Safety (July 29 2019)

- The 2018 sales revenue of the listed drug companies (125) is \$18,172 million in total (7.5% up from the previous year), with Top 10's revenue at \$7,814 million (8.6% ↑).
- * '18 sales revenue (based on consolidated financial statements) : (Yuhan Corporation) \$1,362 million, (Korea Kolmar) \$1,181 million, (GC Green Cross) \$1,181 million, (Guangdong Pharmaceutical) \$1,090 million, (Daewoong Pharmaceutical) \$908 million, (Hanmi Pharm) \$908 million
 - 4 domestic companies are among the top 150 pharmaceutical companies in the world based on prescription drug sales.
 - * '18 prescription drug sales and global ranking (Evaluate 2019): Daewoong Pharmaceutical (111th, \$ 844 million), Hanmi Pharmaceutical (119th, \$ 773 million), Yuhan Corporation (122th, \$ 762 million), Green Cross (139th, \$ 563 million)
- The Korean biologics market is valued around \$2,026 million (2018), accounting for 10.2% of the entire pharmaceutical market, which is lower than the international level (28.2% in 2018).
 - Yet it has very high growth potential, with its production and export values rising greatly at a CAGR of 4.3% and 4.6% respectively, for the last five years (2014-2018).
 - In particular, the biopharmaceutical trade balance has been surplus for four consecutive years following 2015 year due to the increase in exports.
 - Biosimilars in particular are expected to become a next-generation growth engine as 15 of the 20 drugs approved in Korea were developed by Korean companies.
 - * With the focus on biopharmaceutical pharmaceutical companies such as Samsung Biologics and Celltrion, the world's largest biopharmaceutical production facility is being built and in operation (production capacity of 560,000L, more than 70 companies)

Current status of Korean biopharmaceutical market (unit: million dollar, %)

Category	2014	2015	2016	2017	2018	Year-on-year growth rate	CAGR ('14~'18)
Market size	1,885	1,449	1,577	1,974	2,026	2.6%	2.4%
Production	1,597	1,520	1,729	2,300	2,372	3.1%	4.3%
Exports	589	809	1,063	1,368	1,559	14.0%	4.6%
Imports	877	738	911	1,042	1,213	16.4%	3.3%
Trade balance	△288	71	152	326	345	5.8%	-

* Source: Press release by the Ministry of Food and Drug Safety

(Current status of businesses) 571 (72%) of 798 pharmaceutical companies in Korea reported production records for 2018, indicating an average production of 45 items per company.

Current status of Korean pharmaceutical companies (unit: number, %)

Category	2014	2015	2016	2017	2018	CAGR ('14~'18)
Number of manufacturers	851	782	845	806	798	△1.6
Manufacturers with production records	678	597	599	588	571	△4.2
Number of items	29,218	25,890	26,397	26,293	25,939	△2.9
Drug product	18,357	17,907	18,546	19,291	19,239	1.18
Drug substance	10,861	7,983	7,851	7,002	6,700	△11.4
Number of sellers	23,261	24,693	25,862	24,951	26,233	3.1

* Source: Press release by the Ministry of Food and Drug Safety

(Current status of R&D) Striving to enhance competitiveness to the level of advanced countries by launching new drugs developed in Korea in overseas markets through the continuous expansion of R&D investments

- The total R&D investment by the pharmaceutical companies listed in Korea (125 companies) was \$1,423 million in 2018, which accounts for 7.7% of the total sales.
 - The R&D investment by the top 10 companies was \$787 million, which is more than half of the total amount of R&D investment by all the listed pharmaceutical companies, reaching 10.0% of the total sales.
 - The total R&D expenditure of domestic listed innovative pharmaceutical companies (37 companies) accounted for 74% of total listed companies and the proportion of R&D expenses was 9.3%.

R&D investment of major Korean pharmaceutical companies (unit: million dollar, %)

Category		2014	2015	2016	2017	2018
R&D investment	Listed companies	932	975	1,152	1,394	1,423
	Top 10 companies	510	557	712	798	787
	Innovative Pharmaceutical Company	744	798	932	1,125	1,059
Ratio to sales	Listed companies	7.0%	7.1%	7.8%	8.3%	7.7%
	Top 10 companies	10.6%	10.2%	12.1%	11.1%	10.0%
	Innovative Pharmaceutical Company	8.6%	8.6%	9.5%	10.7%	9.3%

* Source: Korea Health Industry Development Institute (KHIDI)

- Due to the increase in the elderly population and chronic diseases, the biopharmaceutical industry, such as cell therapies and gene therapies, continues to expand due to the growing demand for medicines.
 - It is expected that the number of licenses will increase after the establishment of the conditional approval system with 15 items of domestic cell therapies approved by Sewon Cellontech's 'Condrion' ('01') until '18.
 - * It is a new permit system for cell therapy products for the treatment of life-threatening diseases or severe irreversible diseases (Press release by the Ministry of Food and Drug Safety, July 2016).
 - Currently, 7 in stem cell therapies of all items have been released worldwide, of which 4 are developed domestically.
 - * (Pharmicell) Hearticellgram-AMI, (Medipost) Cartistem, (Antrogen) Cupistem, (Corestem) Neuronata-R

(Current status of new drug development) A total of 29 new drugs were developed as of December 2019 by these efforts of Korean pharmaceutical companies.

* 1999-2014: 21 new Korean drugs were developed → 2015-2018: 8 new Korean drugs were developed.

New drugs developed since 2015

Company	Product	Efficacy/Effectiveness	Approval Date
Crystal Genomics Inc.	Acelex Capsule	Treatment for osteoarthritis	February 5, 2015
DongWha Pharm. Co., Ltd.	Zabolante tablet	Antimicrobial agent (antibiotics)	March 20, 2015
Dong-A ST Co., Ltd.	Sivextro tablet Sivextro injection	Antimicrobial agent (antibiotics)	April 17, 2015
Dong-A ST Co., Ltd.	Suganon tablet	Antidiabetic drug	October 2, 2015
Hanmi Pharmaceutical Co., Ltd.	Olita tablet	Cancer drug (lung cancer)	May 13, 2016
Ildong Pharmaceutical Co., Ltd.	Besivo tablet	Hepatitis B treatment	May 15, 2017
CJ Healthcare	K-Cab Tab	gastroesophageal reflux disease (GORD)	July 5, 2018

(Overseas market entry) Korean companies are creating high value-added through the expansion of their global market shares by launching domestically-developed new drugs in the global market and increasing licensing-out to overseas markets.

- 15 Korean drugs have obtained approval in the US and EU since 2014, putting sales to developed markets into high gear.
- SK Biopharm independently proceeded to the third phase of clinical trials and released it to the United States following new drugs developed in Korea, such as XCOPRI ('19), which was approved by the FDA.

Current status of domestically-developed drugs in terms of approval at home and abroad

Company	Trade Name	Reference Drug (Manufacturer)	Efficacy/Effectiveness	Approved in Korea	Approved Overseas	
					EMA	FDA
Dong-A ST Co., Ltd.	Sivextro*	New drug	Oxazolidinone antibiotic	Apr 2015	Mar 2015	Jun 2014
Daewoong Pharmaceutical Co. Ltd.	Meropenem**	Merrem (AstraZeneca)	Carbapenem antibiotic	Apr 2010	-	Dec 2015
	Nabota**	Botulinum toxin (Allergan)	Glabellar wrinkles	Nov 2013	-	Jan 2019
Celltrion Inc.	Remsima*	Remicade (Johnson & Johnson)	Rheumatoid arthritis (RA), ulcerative colitis, etc.	Jul 2012	Aug 2013	Apr 2016
	Truxima*	Rituxan (Roche)	RA, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, etc.	Nov 2016	Feb 2017	
	Herzuma*	Herceptin (Roche)	Breast cancer	Jan 2014	Feb 2018	Dec 2018
	Linezolid**	Zyvox (Pfizer)	Tuberculosis, Wide range of antibiotics	-	-	Apr 2019
	TEMIXYS	Zeffix (GSK), Viread (Gilead)	AIDS	-	-	Nov 2018

Company	Trade Name	Reference Drug (Manufacturer)	Efficacy/Effectiveness	Approved in Korea	Approved Overseas	
					EMA	FDA
Samsung Bioepis Co., Ltd.	Benepali (EU)* Eticobo (US)* Etoloco (Korea)*	Enbrel (Amgen)	RA, psoriasis, etc.	Sep 2015	Jan 2016	Apr 2019
	Flixabi (EU)* Renflexis (US)* Remaroche (Korea)*	Remicade (Johnson & Johnson)	RA, ulcerative colitis, etc.	May 2016	May 2016	Apr 2017
	Imraldi (EU)* Hadlima (US)* Adalloe (Korea)*	Humira (AbbVie)	RA, Crohn's disease, inflammatory bowel diseases, etc.	Sep 2017	Aug 2017	July 2019
	Ontruzant(EU)* Samfenet (Korea)*	Herceptin (Roche)	Breast cancer	Nov 2017	Nov 2017	Jan 2019
SK Chemicals	AFSTYLA	New biologic	Antihemophilic drug	-	Jan 2017	May 2016
SK Biopharmaceuticals	Sunosi	New drug	Sleep disorder	-	-	March 2019
	XCOPRI®	New drug	Epilepsy	-	-	Nov 2019

* Source: Korea Health Industry Development Institute (KHIDI)

(The * mark for the trade name indicates biosimilars, and ** mark for the trade name indicates generic medicine.)

- Large-scale license agreements with global pharmaceutical companies are accelerating exports of technologies developed by Korean pharmaceutical companies.

* A total of 13 worth maximum \$7,181 million in 2019

<License agreements signed by Korean pharmaceutical companies in 2019>

Contract date	Company	Product	Exported to	Partner	Contract Value
Jan	Yuhan Corporation	Non-alcoholic steatohepatitis new drug candidate	US	Gilead Sciences, Inc.	\$785 million
	Green Cross	Hunterase (Hunter's syndrome)	China	CANBridge Pharmaceutical	Private
	TiumBio.	NCE401 (Idiopathic pulmonary fibrosis)	Italy	Chiesi Farmaceutici	\$74 million
Feb	SK Biopharmaceuticals	Cenobamate (Epilepsy)	Swiss	Arvelle Therapeutics	\$530 million
Mar	OliX Pharmaceuticals	OLX301A (Macular degeneration)	France	Thea Open Innovation	\$65 million
	LegoChem Biosciences, Inc.	Antibody-Drug Conjugate ConjuALL™	US	Millennium	\$404 million
April	Green Cross	Hunterase ICV	Japan	Clinigen K.K.	Private
July	Bridge Biotherapeutics, Inc.	BBT-877 (Idiopathic pulmonary fibrosis)	Germany	Boehringer Ingelheim	\$1,230 million
	Yuhan Corporation	YH25724 (Non-alcoholic Fatty Hepatitis)	Germany	Boehringer Ingelheim	\$870 million
Oct	JW Pharmaceutical Corp.	URC102 (Gout treatment)	China	Nanjing Simcere Dongyuan Pharmaceutical	\$70 million
Nov	Quratis	QTP101 (TB vaccine)	Indonesia	PT Bio Farma	\$984 million
	GI Innovation	GI-101 (Dual Fusion Immune Cancer Drug)	China	Nanjing Simcere Dongyuan Pharmaceutical	\$796 million
Dec	Alteogen, Inc.	ALT-B4 (Human hyaluronidase)	-	One of the top 10 global pharmaceutical companies	\$1,373 million

* Source: IR data of the companies

- Based on its technological competitiveness and quality drugs, the pharmaceutical industry in Korea has taken a stride in strengthening its ability to develop innovative drugs in a short period of time, including R&D, clinical trials and drug manufacturing. Impressive growth made in the last few years suggests that Korea based pharmaceutical companies are ready to take a leap forward as global players.

[Pipeline] Development of innovative medicines and strong pipelines across various therapeutic areas

- The local pharmaceutical industry began manufacturing both finished products and drug substances in the 1960s, and developed new processes in the 1980s. Following the early phase of drug development in the late 1980s, Korean pharmaceutical industry began to develop innovative drugs in the 2000s. Since then, Korean pharmaceutical industry has been successfully developing one of the most innovative and incrementally modified drugs.
- Since the introduction of the chemical compound patent system in 1987, the number of innovative drugs introduced in the country has also increased at a very fast pace. Korea has seen development of innovative drugs across various therapeutic areas, from “Sunpla Injection,” a treatment for stomach cancer developed by SK Pharmaceuticals in 1999 to “K-CAP” a treatment for gastroesophageal acid reflux developed by CJ Healthcare in 2018. So far, Korean pharmaceutical companies have developed therapies in an array of areas including oncology, antibacterial, gastritis, respiratory infections, duodenal ulcer, diabetic foot ulcer, erectile dysfunction, hepatitis B and hypertension.



Launch of innovative drugs (total of 29)



Drug Development in Korea

(Clinical Trials) Clinical trials grew dramatically from both qualitative and quantitative perspectives

- Already on a clear growth track with its high level of clinical trial capabilities and reliable data, Korea is emerging as a core clinical trial destination in the pharmaceutical market in Asia. Korea-based 22 major healthcare organizations, including Seoul National University Hospital, Samsung Seoul Medical Center and Asan Medical Center, have won global certifications for their clinical study environment helping the country to build a clinical infrastructure on a global level. With this advanced infrastructure, Korea ranked 7th in the world for global clinical trial protocol market share in 2018, moving one level down from the 6th at the previous year. The number of domestic clinical trials came to 679 in 2018, up nearly 3.2% compared to 658 in 2017. Its share in global clinical trials decreased from 3.51% in 2017 to 3.39% in 2018.
- The number of multinational regional clinical trials (MRCTs) conducted by multinational pharmaceutical companies in Korea has also increased sharply since the country introduced International Conference on Harmonization Good Clinical Practice (ICH GCP) in 2000. Especially, Pfizer formed a partnership with Korea as part of its global clinical program in 2008, selecting 4 of its 9 global Core Research Sites (CRSs) in Korea.
- The ongoing “Smart Clinical Trial Platform” program that involves major 7 hospitals is expected to contribute to achieving higher clinical trial efficiency of Korea under the assumption that the platform technologies to be developed through this program are widely adopted by Korean hospitals. Active use of the EMR data in conducting feasibilities and matching patients with the complex inclusion/exclusion criteria would greatly improve efficiency together with a more streamlined and transparent clinical trial authorization process by Korean health authorities (Reference: Chee DH. Korean clinical trials: its current status, future prospects, and enabling environment. *Transl Clin Pharmacol.* 2019;27(4):115-118).

[Manufacturing] High level of competitiveness and ability to generate rich pipelines of innovative drugs

- Pharmaceutical companies in Korea have been working to ensure that their drug manufacturing facilities meet rigorous global standards. To reflect global trends, the guidelines on Good Manufacturing Practices(GMP) changed from dosage forms to prior approval of individual items in 2008. As the guidelines shifted from management of dosage forms to that of individual items based on a step-by-step process through 2010, the quality assurance system for domestically manufactured drugs reached a global level.
- In addition, Korea has the ability to conduct drug R&D for compounds and commercial technologies, including organic synthesis, agents and global clinical trials. This ability was gained through development of generics and incrementally modified drugs. Korea is also a leader in the pharmaceutical biological technology area. With fruitful results from R&D including development of the world’s first stem cell therapy and xenotransplantation of pancreatic ducts, Korea is in an advantageous position to be a leader in promising future industries. The level of therapeutic technologies in cardiac surgery and management, and cervical cancer in Korea is the best among other OECD countries, according to OECD Health Data 2009.
- Korea pharmaceutical industry is shifting its focus from the domestic market to the global market, and the world now pays attention to Korean pharmas as successful partners.

Introduction of Korean Innovative Pharmaceutical Company Certification System

1. Public-private Partnership for Development of Pharmaceutical Industry Contributing to Global Health

Korea aspiring to transforming itself into one of the top seven pharmaceutical powerhouses

Korea has designated the pharmaceutical industry as one of the future growth engines. In order to foster the industry, the Korean government has been placing emphasis on enhancing growth potential through far-reaching policy measures, ranging from technology innovation to promoting market transparency, boosting global competitiveness of companies, and establishing infrastructure for sustainable development. Moreover, with knowledge and capacity mustered, the government, industry, medical society, and academic community are devoting themselves to make a leap forward into global markets. Under the circumstance where the Korean population has been aging rapidly, the Korean government has keen interest in the pharmaceutical industry, which serves as a foundation for the quality of life of the public. The government introduced "Accreditation of Innovative Pharmaceutical Company" in 2012, and will reinforce its efforts to support the industry every year with a view to reinventing the nation into one of the top seven pharmaceutical titans.

2. Introduction of Promotion and Support of Innovative Pharmaceutical Company

2-1. What Company Can Be an Innovative Pharmaceutical Company?

Special Act on Pharmaceutical Industry Promotion and Support (enacted in March 2011) serves as the legal foundation to designate innovative pharmaceutical companies verified to possess high R&D capacity for new drug development and to be globally competitive. Those companies are expected to play a leading role in developing the domestic pharmaceutical industry into a future growth engine.

In particular, 'innovative pharmaceutical company' is the government's ambitious pharmaceutical industry fostering policy adopted as a concept that refers to a company that has been recognized as having superior capability in new drug development as well as overseas expansion based on the 'Special Act on Fostering and Supporting the Pharmaceutical Industry'. To cope with the rapid changes in the environment surrounding the pharmaceutical industry, such as during price cuts and effect of the Korea-US FTA, the Ministry of Health and Welfare aims to support the 'innovative pharmaceutical company' with research, development and overseas advancement capability as the core of '2012 Pharmaceutical Industry Competitiveness Enhancement Plan', which was arranged together with the related ministries in January 2012, to foster Specialized Pharma which is specialized in specific medical conditions, Global Generic Pharma which does mass production of generics, or Global Major Pharma which is at the level of advanced multinational corporations. This is a big sketch that government has envisioned.

Above all, 'innovative pharmaceutical company' was accepted as a very honorable medal to select the companies that play a leading role in fostering domestic pharmaceutical industry as future growth engine industry. Moreover, 'innovative pharmaceutical company' will be the scale to read the will of the government to cultivate the pharmaceutical industry in the future since it is the only carrots proposed by the government, which has consistently been in whipping, including the introduction of the rebate dual punishment system and implementation of the batch drug price cut.

2-2. What are the Criteria for Selecting an Innovative Pharmaceutical Company?

In order to be selected as an innovative pharmaceutical company, it was necessary to have a research and development investment or facilities of a certain scale or more. In other words, the R&D expenditure relative to average gross drug sales in the last 3 years has had to meet the requirements as follows: 1) companies with an annual sales of more than KRW 100 billion would have a R&D cost of at least 5%, 2) companies with less than KRW 100 billion would have a R&D cost of more than 7% or an absolute amount of more than KRW 5 billion, and 3) for US or EU GMP facilities, a R&D cost relative to sales would be at least 3%.

2-3. Accreditation Process

The Accreditation Screening Committee conducted written and verbal evaluations on candidate pharmaceutical firms which met the requirements (Article 2 of the Enforcement Decree of the Special Act: investment volume over a certain level). In the evaluations, the committee assessed candidate companies based on specific requirements, such as R&D performance in the past, company's capacity, vision and investment plan, ethical business practice, etc. The results of the evaluations delivered by the screening committee were finalized after the review carried out by the Committee for Pharmaceutical Industry Promotion and Support, which is chaired by the Minister of Health and Welfare.

2-4. Composition of Designated Innovative Pharmaceutical Companies

- General pharma firms [31]: 31 leading firms that have marked high scores in terms of R&D investment as well as researchers, manufacturing facilities, patent and license-out, and overseas market advancing plus ten SMEs that have built on expertise in specialized areas such as development of incrementally modified drugs
- Bio venture companies [9]: firms with relatively low sales but highly competitive technology and creative business models
- Multinational pharma firms [4]: one local company of an MNC considered outstanding in terms of R&D investment (in early clinical trials), local production performance, overseas market advancing, etc.

2-5. List of Companies Certified as Innovative Pharmaceutical Companies [44]

(May, 2020)

Category	Name of Company
General pharma firms [31]	Boryung Pharm, Bukwang Pharm, Celltrion, Chong Kun Dang Pharm, Dae Hwa Pharm, Daewon Pharm, Daewoong Pharm, GC Pharma, Handok, Hanlim Pharm, Hanmi Pharm, HK inno.N, Huons, Hyundai Pharm, Ildong Pharm, Isu Abxis, JW Pharm, Kolma Korea, Korea United Pharm, Kuhnii Pharm, LG Chem, Pharma Research Products, Pharmicell, Samjin Pharm, Samyang BioPharm, Shin Poong Pharm, SK Chemicals, ST Pharm, Taejoon Pharm, Yuhan, Yungjin Pharm
Bio venture companies [9]	ABL Bio, Alteogen, BC World Pharm, Corestem, CrystalGenomics, Genexine, Helixmith, Medytox, Tego Science
Multinational pharma firms [4]	AstraZeneca Korea, Janssen Korea, Korea Otsuka Pharm, Sanofi-Aventis Korea



ABL Bio, Inc.

CEO
Sang Hoon Lee

Location
2nd Floor, 16 Daewangpangyo-Ro 712 Beon-Gil,, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, 13488, South Korea

Specialty
Immuno-oncology Therapeutics, Multispecific Antibody, BBB-penetrating Platform Technology

Tel / Fax / E-mail
T. 82-31-8018-9800
F. 82-31-8018-9836
E. Info@ablbio.com

ABL Bio founded in 2016 is a fast growing biotechnology company developing novel innovative antibody therapeutics in the field of immuno-oncology and neurodegenerative diseases. ABL Bio develops more than 20 pipelines based on an unique bispecific antibody (BsAb) platform technology. ABL001 is the most advanced BsAb asset, targeting VEGF and DLL4, which is ongoing phase 1 clinical study. ABL Bio's BsAb platform technology enables to connect two different antibodies together, ensuing synergistic activity of the two antibodies. Grabody™ T belongs to a T cell engaging bispecific antibody and Grabody™ I is a dual immune modulating bispecific antibody for cancer treatment. Grabody™ B is a bispecific antibody using blood-brain barrier (BBB)-penetrating platform for neurodegenerative disease treatment.

Main Products



ABL001(NOV1501)

Product type	specific indication	Development Stage
ABL001(NOV1501)	a bispecific antibody therapeutics for malignant solid tumor	scheduled to conduct clinical trials of 1b/2

CONTACT US

Technology Transfer / Licensing

Weonkyoo You
R&D/Head of R&D
T. +82-31-8018-9803
E. weonkyoo.you@ablbio.com

Overseas export

Weonkyoo You
R&D/Head of R&D
T. +82-31-8018-9803
E. weonkyoo.you@ablbio.com

Overseas Office

Bryan Kang
Planning&Strategy/
Head of Department
T. +1-734-707-3715
E. bryan.kang@ablbio.com

Etc.

Da Woon Lee
Business Operations/
Principal Manager
T. +82-31-8018-9821
E. dawoon.lee@ablbio.com

R&D Pipeline

		Indication	Early Discovery	Late Discovery	Pre-Clinical	Phase I	Phase II/ III
Angiogenesis	ABL001 (Anti-VEGF/DLL4 BsAb)	Solid Cancer	[Progress bar]			[Icon]	[Icon]
Antibody-Drug Conjugate (ADC)	ABL20X	Cancer	[Progress bar]			[Icon]	[Icon]
NexMab™ (ADC)	Grabody™ T(4-1BB) (Multiple Pipelines) ABL10X	Cancer	[Progress bar]			[Icon]	TAAx4-1BB BsAb
	Grabody™ I (PD-L1) ABL50X	Cancer	[Progress bar]			[Icon]	PD-L1xLAG3 PD-L1x4-1BB BsAb
	I/O mAb ABL40X	Cancer	[Progress bar]	[Icon]			Novel I/O mAb
SC drug delivery	Grabody™ B ABL301 (α-Synuclein / IGF1R)	Parkinson's Disease	[Progress bar]			[Icon]	



ALTEOGEN Inc.

ALTEOGEN, located in Daejeon, South Korea, is a biotech venture company established in 2008. ALTEOGEN has developed proprietary NexP™, NexMab™ and Hybrozyme® platform technologies for long-acting biobetters, site-specific conjugated ADC and novel recombinant human hyaluronidase, respectively. ALTEOGEN aim to transform and improve care for the lives of those who are suffering from serious diseases, in search of therapies with our cutting-edge science and technology. ALTEOGEN was listed on KOSDAQ in 2014.

Main Products

Product type		Code name	indication	specific indication	Development Stage
Novel Biologics (Biobetter)	Recombinant fusion protein	ALT-P1	Growth hormone deficiency	Growth hormone deficiency	Phase 2
	Antibody drug conjugate	ALT-P7	Oncology	Breast cancer	Phase 1
	Recombinant protein	ALT-B4	Subcutaneous Absorption Accelerator	Oncology	Pre-clinical
Biosimilar		ALT-L9	Ophthalmic diseases	Wet Age Macular Degeneration	Phase 1
		ALT-LS2	Oncology	Breast cancer	Pre-clinical

R&D Pipeline

Technology	Pipeline	Research	Process Dev.	Pre-clinic	Phase 1	Phase 2	Phase 3	
NexP™ (Biobetter)	Long-acting hGH, ALT-P1 (hGH deficiency)							
	Long-acting E1-FGF21, ALT-FL1 (NASH)							
NexMab™ (ADC)	Breast/Gastric cancers, ALT-P7							
	Ovarian cancer, ALT-Q5							
Biosimilars	Herceptin® SC biosimilar, ALT-LS2 (Breast/Gastric cancer)							
	Eylea® biosimilar, ALT-L9 (wAMD)							
SC drug delivery	Novel Hyaluronidase (ALT-B4)							

CEO
Soon Jae Park, Ph.D.

Location
62, Yuseong-daero 1628beongil, Yuseong-gu, Daejeon, 34054, Korea

Specialty
 1. NexMab™ Technology for site-specific ADC conjugation
 2. NexP™ Technology for long-acting biobetter recombinant therapeutics
 3. Hybrozyme™ Technology for the novel human recombinant Hyaluronidase

Tel / Fax / E-mail
 T. 82-42-384-8780
 F. 82-42-384-8770
 E. info@alteogen.com

CONTACT US

Technology Transfer / Licensing

Hee Ho Cho
 BD/Manager
 T. +82-70-7721-8755
 E. erica.hh.cho@alteogen.com

Overseas Office

Arun Swaminathan, Ph.D.
 BD/CBO
 T. +1-609-937-8767
 E. arun@alteogen.com

Etc.

Min Suk Lee, Ph.D.
 Strategic Planning/
 Senior Vice President
 T. +82-42-384-8780
 E. superlee63@alteogen.com



BC WORLD PHARM. CO., LTD.

BC World Pharm. Co., Ltd.(BCWP) has expertise in formulation and process development to provide quality generics. BCWP is not only certified as Korea Innovative pharmaceutical company, but also designated as Advanced Technology Center. In 2019, Carbapenem injections facility has been completed its construction in Wonju city. Starting with the commercialization of Carbapenem product, BCWP is preparing to enter global market such as US and Japan. Accordingly, the inspections for cGMP and PMDA are scheduled in this year.

Main Products



Meropenem 1g



Meropenem 500mg

Therapeutic class	Products	Remarks
Antibiotics (Carbapenem)	Meropenem Inj., Imipenem+Cilastatin Inj., Ertapenem Inj., Etc	Launched
Anti-Infectives	Vancomycin Inj., Metronidazole Gel., Etc.	Launched
Anti-TB	Rifampicin+Isoniazid+Pyrazinamide+Ethambutol Tab.	Launched
Anti-Hyperlipidemia	Atorvastatin Tab., Rosuvastatin Tab.	Launched
Anti-Hypertensive	Nicardipine HCl Inj., Amlodipine+Valsartan Tab., Etc	Launched
Gastrointestinal Agents	Rebamipide Tab., Etc	Launched
Narcotics	Fentanyl Sublingual Tab., Fentanyl Inj., Remifentanyl Inj., Morphine Inj., Etc.	Launched
Well-being Product	Glutathione Inj., Zinc sulfate hydrate Inj., Ascorbic Inj., Multipotent Inj. (Zn, Cu, Se, Cr, Mn, F, Fe, I, Mo), Etc.	Launched

R&D Pipeline

Category	Item	Indications	Stage	
Injection	BCWP_D001	Anti-cancer	Pre-clinical	
	BCWP_D003	Anti-cancer	Pre-clinical	
	BCWP_D006	Anti-cancer	Pre-clinical	
	BCWP_D007	Parkinson's disease	Pre-clinical	
	BCWP_D008	Osteoarthritis pain of the knee	Formulation	
	BCWP_D009	Anti-psychotic	Pre-clinical	
	BCWP_D010	Anti-psychotic	Phase 1	
	BCWP_D011	Anti-psychotic	Pre-clinical	
	BCWP_D012	Anti-psychotic	Pre-clinical	
	Oral Dosage Form	BCWP_E008	Anti-Parkinson	Formulation
		BCWP_C003	Anti-hyperlipidemia	Phase 1
		BCWP_G1904	Antihistamine	Formulation
BCWP_G1905		Antispasmodic	Formulation	

CEO
Sung Han Hong

Location
Gyung Building, 78, 22-gil, Gaepo-ro, Gangnam-gu, Seoul, Republic of Korea

Specialty
1. Incrementally Modified Drugs
2. Drug Delivery System (DDS)
3. Generic

Tel / Fax / E-mail
T. 82-2-2181-0400
F. 82-2-574-5064
E. tree365@bcwp.co.kr

CONTACT US

Technology Transfer / Licensing

Lena Jung
Global Business Team/
BD Manager
T. +82-2-2182-0466
E. lenajung@bcwh.co.kr

Overseas export

David Kim
Global Business Team/Director
T. +82-2-2182-0432
E. tree365@bcwp.co.kr



Boryung pharmaceuticals Co., Ltd.

CEO
Jae-hyun Ahn, Sam-soo Lee

Location
136, Changgyeonggung-ro,
Chongro-ku, Seoul

Specialty
1. Hypertension NCE
2. Oncology NCE
3. Cardiovascular disease IMD

Tel / Fax / E-mail
T. 82-2-708-8000
F. 82-31-491-5340

Boryung Pharmaceutical strives to be a company which will continue to practice 'contributing to the health of mankind' by preparing for the future and taking on challenges with innovation. We have made every effort to free everyone from the pains of disease. As a result, the people of Korea have come to love our products.

We has developed Kanarb, the No. 1 ARB in Korea, and kanarb combination drugs by our proprietary technology. We has successfully licensed out Kanarb Family to 38 countries.

Main Products

Product (Ingredient)	Use	Exporting Countries	Remarks
Kanarb (Fimasartan)	Hypertension	13 Latin countries, Russia, China, 13 Southeast Asian countries, 10 African countries	Launched
Dukarb (Fimasartan+Amlodipine)	Hypertension	25 Latin countries, 13 Southeast Asian countries, 10 African countries	Launched
Tuvero (Fimasartan+Rosuvastatin)	Essential hypertension and dyslipidemia	25 Latin countries, 13 Southeast Asian countries	Launched
Kanarb plus (Fimasartan+HTCZ)	Hypertension	13 Latin countries, 13 Southeast Asian countries, 8 African countries	Launched
Dukaro (Fimasartan+Amlodipine+Rosuvastatin)	Hypertension and dyslipidemia		Launched
Gelfos M (Colloidal Aluminum Phosphate, Magnesium hydroxide, Simethicone)	Gastric antacid	China, Taiwan	Launched
Besto (Lafutidine)	Gastric ulcer		Launched

R&D Pipeline

		Indication	Discovery	Preclinical	Phase I	Phase II	Phase III	Launch
NCE	BR2002	Lymphoma						
	BR2006	Cancer						
	BR2007	Cancer						
IMD	BR1006	Hypertension Dyslipidemia						
	BR1007	CKD						
	BR1008	Hypertension Dyslipidemia						
	BR1009	Hypertension Diabetes						
	BR1010	Hypertension						
	BR4002	Alzheimer's disease						

CONTACT US

Technology Transfer / Licensing

JiHyun Min
Open innovation team/
Assistant manager
T. +82-31-491-2771(892)
E. minjyun@boryung.co.kr



Bukwang Pharmaceutical Co., Ltd.

Bukwang, founded in 1960, is dedicated to bringing novel and outstanding medicines to the public.

As in-house developed products, Levovir® was developed as the 4th new drug in the world for hepatitis B and licensed out to Asia. Dexid® was developed for the treatment of diabetic neuropathy and is to be exported to East-Asia.

Bukwang has been actively investing in R&D, and continuing to pursue new drug development with various partners worldwide.

Main Products



Levovir®



Dexid®

Product (ingredient/formulation)	Indication	Exporting countries	Remarks
Levovir® capsule (Clevudine)	Chronic hepatitis B virus infection	Philippines	Launched
Dexid® tablet (R-thioctic acid tromethamine)	Diabetic polyneuropathy	East-Asian countries	Launched

R&D Pipeline

TA	Project	Indication	Category	Development phase				
				Discovery	Preclinical	Phase I	Phase II	Phase III
CNS	Lurasidone	Schizophrenia/ bipolar depression	Chemical	[Progress bar]				[Progress bar]
Metabolism	MLR-1023	T2DM		[Progress bar]				
CNS	JM-010	Dyskinesia		[Progress bar]				
Oncology	SOL-804	Prostate cancer		[Progress bar]				
Immunology	BKC-1501A	Immune disorders		[Progress bar]				
Metabolism	BK-1701	Anti-diabetes/ Obesity		[Progress bar]				
CNS	USP8 Program	Neurodegeneration		[Progress bar]				
I-O	AhR inhibitor	Cancers		[Progress bar]				
CNS	PKR inhibitor	Neurodegeneration		[Progress bar]				

CEO
Hee-Won Yoo

Location
7, Sangdo-ro, Dongjak-gu, Seoul, Korea

Specialty

- CNS Small molecules
- Metabolic disorder Small molecules
- Oncology Small molecules (including IMDs)

Tel / Fax / E-mail
T. 82-2-8288-114
F. 82-2-8288-029

CONTACT US

Technology Transfer / Licensing

E. bizcontact@bukwang.co.kr

Overseas export

E. bizcontact@bukwang.co.kr

Overseas Office

E. bizcontact@bukwang.co.kr

Etc.

E. bizcontact@bukwang.co.kr



A global pharmaceutical company that promotes health and welfare for all



www.celltrion.com/en-us

Celltrion, Inc.

CEO
Kee Woo Sung

Location
23 Academy-ro, Yeonsu-gu,
Incheon Metropolitan City

Specialty
Biosimilars, New Drugs, Small
Molecules

Tel / Fax / E-mail
T. 82-32-850-5000
E. Contact@celltrion.com

Celltrion, Inc. is a leading Korean biopharmaceutical company that launched the world's very first antibody biosimilar product, Remsima®. As one of the first companies to chart the Korean biopharmaceutical sector, Celltrion pioneered many previously unexplored areas and evolved into one of the leaders in the biosimilar development and manufacturing sector with numerous milestone achievements. The company now plans to keep the momentum and continue the legacy as it ventures into new business areas such as small molecule pharmaceuticals and Ubiquitous-healthcare system with unique Celltrion approaches.

Main Products



Remsima



Truxima



Herzuma

Biopharmaceutical

Product	Reference Product	INN	Indications
Remsima SC	-	Infliximab	Rheumatoid Arthritis
Remsima / Inflectra	Remicade	Infliximab	Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease, Psoriasis
Truxima	Rituxan	Rituximab	Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis
Herzuma	Herceptin	Trastuzumab	HER2-Positive Metastatic Breast Cancer, Early Breast Cancer, Metastatic Gastric Cancer

Small molecule

Product	Ingredient	Indications
Linezolid	Linezolid	Pneumonia, Skin and Skin Structure Infections, Vancomycin-resistant Enterococcus faecium Infections

R&D Pipeline

Antibody Biosimilars

Project	INN	Original	Indications	Status
CT-P39	Omalizumab	XOLAR®	Asthma, Urticaria	Research
CT-P17	Adalimumab	HUMIRA®	Rheumatoid arthritis, Psoriatic arthritis, IBD	Phase3
CT-P16	Bevacizumab	AVASTIN®	Metastatic Colorectal Cancer, Metastatic Breast Cancer, NSCLC	Phase3

New Antibodies

Project	Indications	Status
CT-P59	COVID-19	Research
CT-P27	Pandemic-Seasonal influenza	Phase2

IMDs

Project	Indications	Status
CT-G20	Cardiomyopathy	Clinical trial

CONTACT US

Yong Gun Sung
Strategic Planning Department/
Asst. Manager
T. +82-32-850-8496
E. yonggun.sung@celltrion.com



CHONG KUN DANG

www.ckdpharm.com/en/home

Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with a goal of supplying the best quality medicines. In 1968, CKD received US FDA approval for Chloramphenicol. Remarkably, CKD is one of the first Korean pharmaceutical companies to establish Research Center in early 1970's to accelerate the development of novel technologies and therapeutics. As a result, CKD has successfully launched two novel therapeutics, Camtobell for anti-cancer and Duvie for type 2 diabetes, and world's first NESP biosimilar, Nesbell.

Main Products



Category	Brand Name	Ingredients	Note
Oncology	Camtobell Inj	Belotecan	New Drugs
Type 2 diabetes	Duvie Tab	Lobeglitazone	New Drugs
Antihypertensive drugs	Dilatrend Tab	Carvedilol	
Immunology	Tarcobell Cap	Tarcrolimus	
Antihyperlipidemic agent	Lipilou Tab	Atrovastain	
Nootropic Agents	CKD Gliatilin Soft Cap	Choline Alfoscerate	

CEO
YOUNG JOO KIM

Location
8 Chungjeong-ro, Seodaemun-gu, Seoul, Korea

Specialty
1. Anticancer New Drugs
2. Antidiabetic New Drugs
3. Autoimmune Diseases

Tel / Fax / E-mail
T. 82-2-2194-0300
F. 82-2-2194-0369
E. youngjookim@ckdpharm.com

R&D Pipeline

New Chemical Drugs/Biologics

CV & METABOLIC DISEASE

- Diabetes (PPAR-γ agonist)
- Dyslipidemia (CETP inhibitor)

ONCOLOGY

- Ovarian Cancer, SCLC (Camptothecin analogue)
- Liver Cancer (A3 adenosine receptor agonist)
- Colorectal Cancer (VDA)
- Multiple Myeloma (Pan-HDAC inhibitor)
- NSCLC, Colorectal Cancer (Bi-specific antibody)

IMMUNOLOGY

- SLE, Dermatomyositis (anti-INFα)
- Autoimmune Disease (HDAC6 inhibitor)

CNS

- Neurodegenerative Disease (HDAC6 inhibitor)

OTHERS

- Anemia (Darbepoetin-α)
- Ophthalmology (Ranibizumab)
- Pain, Uremic Pruritus (Opioid κ receptor agonist)
- HSDD (Hypoactive sexual desire disorder)
- Rare Disease (HDAC6 inhibitor)



∞ Biologics / * In-licensed product

CONTACT US

Technology Transfer / Licensing

Rachel Eunjin Shim
Business Development Team/
Team Manager
T. +82-2-2194-0414
E. ellej800@ckdpharm.com

Overseas export

Il Hyeong Cheong
Global Business Planning Team /
Team Manager
T. +82-2-2194-0423
E. ihch@ckdpharm.com



CORESTEM creates new hope for treatment of intractable diseases.

Corestem, Inc

www.corestem.com/en/

CEO
Kyung Suk Kim

Location
24, Pangyo-ro 25 beong-gil,
Bundang-gu, Seongnam-si,
Gyeonggi-do, Korea

Specialty
Stem Cell Therapy

Tel / Fax / E-mail
T. 82-2-497-3711
F. 82-2-6349-8666
E. corestem@corestem.com


CORESTEM is a bio-pharmaceutical company specializing in research and development of personalized stem cell therapies for incurable disease. We developed the world's first stem cell therapeutic product for ALS (Amyotrophic Lateral Sclerosis), name of Neuronata-R®. Corestem's research and development is focused on advancing preferred stem cell treatments for intractable diseases, driving scientific advancement, and expanding patient care offerings.

Main Products



	Product	Ingredient	Use
Neurological Disease	Neuronata-R®	Autologous bone marrow derived mesenchymal stem cell (lenzumeastrocel)	Mitigation of amyotrophic lateral sclerosis (ALS) progression.

R&D Pipeline



CONTACT US

Technology Transfer /
Licensing

Hyoun Woo Kim
Strategic Business Dept/ RA/MA
Manager
T. +82-70-4706-9610
E. hwkim@corestem.com



CrystalGenomics, Inc.

www.crystalgenomics.com/en

CrystalGenomics is a commercial stage biopharmaceutical company dedicated to the R&D and commercialization of novel pharmaceuticals to address significant unmet medical needs in the therapeutic area of infectious disease, oncology and inflammatory diseases. CrystalGenomics has a marketed product, Acelex (Polmacoxib), which has been approved by the MFDS and several export agreements has been signed with several countries. In addition to Acelex, CrystalGenomics is developing several first-in class/best-in class drug candidates.

Main Products



Acelex Tablet



Acelex Capsule

Products (Ingredient/Formulation)	Use	Exporting Countries
Acelex (Polmacoxib) 2mg Capsule	Nonsteroidal anti-inflammatory drug for osteoarthritis	Turkey & MENA 19 countries, Brazil, Eurasian Economic Union (Russia, Belarus, Kazakhstan, Kyrgyzstan, Armenia)
Acelex (Polmacoxib) 2mg Tablet	Nonsteroidal anti-inflammatory drug for osteoarthritis	

R&D Pipeline

Area	Program	Indications	Preclinical	Ph 1	Ph 2	Ph 3
Pain/ Inflammation	CG-650	Acute/Chronic Pain				
	CG-651 ⁽¹⁾	Neuropathic Pain				
	CG-598 ⁽²⁾	Inflammatory Bowel Disease				
Anti-Infective	CG-549 ⁽¹⁾	MRSA		Global Clinical trial		
Oncology	Ivaltinostat ⁽²⁾	Pancreatic Cancer		MFDS/FDA Orphan Drug Designation		
	Ivaltinostat ⁽²⁾	MDS		MFDS Orphan Drug Designation		
	Ivaltinostat ⁽²⁾	AML			Global Clinical trial	
	Ivaltinostat + Anti-PD-1 Antibody	HCC ⁽¹⁾			Global Clinical trial	
	CG-806 ⁽¹⁾	AML, MCL, CLL		APTOSE BIOSCIENCES	Global Clinical trial	
Fibrosis	CG-750 ⁽²⁾	Fibrosis				

(1) First-in-class
(2) Best-in-class

CEO
Joong Myung Cho

Location
CrystalGenomics, Inc., 5th F, Bldg A, Korea Bio Park, 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea

Specialty
1. Inflammatory disease
2. Oncology
3. Infectious disease

Tel / Fax / E-mail
T. 82-31-628-2720
F. 82-31-628-2701

CONTACT US

Technology Transfer / Licensing

Steven Kim
Business Development/
Executive Director
T. +82-31-628-2720
E. skim@cgxinc.com

Overseas export

Steven Kim
Business Development/
Executive Director
T. +82-31-628-2720
E. skim@cgxinc.com

Overseas Office

Steven Kim
Business Development/
Executive Director
T. +82-31-628-2720
E. skim@cgxinc.com

Etc.

Gwang Su Kim
Strategy Planning Team/Manager
T. +82-31-628-2718
E. gskim@cgxinc.com



The dream of prolonging life into reality

DAEHWA Pharm

www.dhpharm.co.kr

CEO
Byung-Tae No, Eun-Seok Kim

Location
24, Pangyo-ro 25 beong-gil,
Bundang-gu, Seongnam-si,
Gyeonggi-do, Korea

Specialty
New anticancer combination
drug, Incrementally modified
drug, Biosimilar, First generic

Tel / Fax / E-mail
T. 82-2-586-6451
F. 82-2-587-0566

Daehwa, with spirit of “serving society to create a better place for human being through pharmaceutical business”, has a goal to improve quality of life with respect for human life. Core technologies such as DHLASED, are used to develop drugs in various fields, to be a pioneer for new paradigm, and by cooperating with global partners, Daehwa is currently exporting products to 20 different countries. In 2017, Daehwa acquired German medical device and cosmetic company to expand to new area with its unique know-how on the aesthetic fields.

Main Products

Product (Ingredient/Formulation)	Use	Exporting Countries	Remarks
Methylol cephalixin lysinate	Antibiotics	-	Launched
Phloroglucinol	Antispasmodic	-	Launched
Diacerein	Osteoarthritis	Ecuador, HongKong	Launched
Warfarin sodium	Antithrombotic agent	Bolivia, Ecuador	Launched
Ginseng, Vitamin	Nutrient	Taiwan, Bolivia 외	Launched

CONTACT US

Technology Transfer / Licensing

CHO YOUNG-SANG
BD/Manager
T. +82-2-6716-1072
E. crispaul@dhpharm.co.kr

Overseas export

SEO HAN WONG
Overseas business team /Director
T. +82-2-6716-1071
E. shw0817@dhpharm.co.kr

Etc.

CHUNG JEAN-AH
Deveopment/Manager
T. +82-2-6716-1052
E. jina@dhpharm.co.kr



Daewon Pharm. Co., Ltd.

www.daewonpharm.com/eng/main/index.jsp

Daewon Pharmaceutical's believe that customers is the most important core value of corporate management. Since Established in 1958 based on the founding philosophy of "partner for people to promise their healthy lives", we have effort to protect the healthy life of people as a company specialized in pure competent pharmaceutical company.

Daewon Pharm is a pharmaceutical company that based on its advanced facility & Plant, investment and excellent R&D capabilities, we have developed the ' Pelubi Tab', a new drug for the Korean & Global market.

Main Products

Category	Product	Molecule
Analgesic	Pelubi CR Tab.®	Pelubiprofen
	Pelubi Tab.®	Pelubiprofen
	Nerexone SR Tab.	Eperisone
Cardiovascular	Clow Tab.	Rosuvastatin
	Lipiwon Tab.	Atorvastatin
	Exombi Tab.	Varsartan/amlodipine
	TG Fenone Tab.	Choline Fenofibrate
	Twincombi Tab.	Telmisartan/amlodipine
	Tri-in-one Tab.	Telmisartan/amlodipine/Rosuvastatin
	Uptava Cap.	Pitavastatin/Fenofibrate
Gastrointestinal	Eswonamp Tab.	Esomeprazole
	Otillen F Tab.	Artemisia herb isopropanol soft extract(20→1)
Respiratory	Codaewon Forte Syr.	Dihydrocodeine/ammonium chloride /chlorpheniramine/dl-methylephedrine
	Beposta SR Tab.	Bepotastine
	Beposta SR Tab.	Bepotastine
	Elsteine Tab.	Erdosteine
Analgesic	Wontran ER Tab.	Acetaminophen/Tramadol
	Lycaneuro ER Tab.	Pregabalin
	Freefol MCT Inj.1,2%	Propofol
Others	Renamezin Cap.	Spherical adsorptive carbon

R&D Pipeline

Category	Project Code	Indication	Stage
New chemical entity	DW-4301	Cardiovascular Disease	Phase I
	DW-4902	uterine disease	Phase I
Generic	DW-2801	Gastrointestinal disease	Phase I
	DW-5903	Cardiovascular Disease	Pre-Clinical
Incrementally modified drug	DW-1601	Respiratory Disease	Phase III
	DW-1807	Respiratory Disease	Phase I
	DW-1806	Metabolic Disorders	Phase I
	DW-1805	Metabolic Disorders	Pre-Clinical
	DW-8809	Gastrointestinal disease	Pre-Clinical
	DW-1804	Metabolic Disorders	NDA submit
	DW-1808	degenerative disease	Pre-Clinical
	DW-1809	degenerative disease	Phase I

CEO
Seung Ryel Baek

Location
386 cheonhodaero-ro, Seongdong-gu, Seoul #04808, Korea

Specialty
1. IMD (incrementally modified drug)
2. NCE (New chemical entity)
3. First Generic

Tel / Fax / E-mail
T. 82-2-2204-7000
F. 82-2-3436-4878

CONTACT US

Technology Transfer /
Licensing

MINPYO KIM
Business Development/Manager
T. +82-2-2204-6960
E. nuboti@daewonpharm.com

Overseas export

DONGWOO KANG
Overseas Business Dept./Manager
T. +82-2-2204-6971
E. dongwoo79@hotmail.com



A global healthcare group dedicated to improving quality of life

Daewoong Pharmaceutical Co., Ltd.

www.daewoong.co.kr

CEO
Jeon Seng Ho

Location
Bongeunsa-ro 114-gil 12 Gangnam-gu Seoul 06170 Korea

- Specialty
1. new chemical entities for intractable disease
 2. stem cell therapy for rare diseases (cell & gene therapy)
 3. new formulation technology

Tel / Fax / E-mail
T. 82-2-550-8533
F. 82-2-550-8400
E. stomeve@daewoong.co.kr

Since 1945, we have grown into Korea's leading company in line with corporate philosophy of 'developing quality medicine to safeguard the people's health and contribute to a healthier society.'

With \$1.3B revenues, we have 8 manufacturing sites globally and branches in China, Japan, Indonesia, Thailand, Vietnam, Philippines, India and USA. We are the no.1 Korean player in Chinese GI market, and we acquired the no.2 Vietnamese company (Traphaco). We have the first Halal certified Indonesian bio facility and a POC center in India.

Main Products

Brands

Product name	Description
Ursa®	Liver diseases & dysfunction improvement
Bearse®	Multilayer digestives



Biologics

Product name	Description
Easyef® (EGF)	Diabetic foot ulcer, Acute wounds
Novosis® (rh BMP-2)	Dental sinus lift graft
Caretropin® (hGH)	Growth hormone deficiency
Eposis® (EPO)	Anemia in chronic kidney disease
Nabota® (Botulinum toxin)	Anti-wrinkles



Formulation

Product name	Description
Luphere® Depot	Peptide delivery system for prostate cancer
lostar	New combination drug for Hyperlipidemia/hypertension



CONTACT US

Technology Transfer / Licensing

Doyoung Kim
Global Development Center / Head
T. +82-10-7474-4247
E. Doyoung.kim@daewoong.co.kr

Overseas export

Doyoung Kim
Global Development Center / Head
T. +82-10-7474-4247
E. Doyoung.kim@daewoong.co.kr

Overseas Office

LEE JOO HONG
Global Business Team / Team Manager
T. +82-10-9204-6033
E. hellojohn@daewoong.co.kr

R&D Pipeline

	Research	Pre-clinical	Phase I	Phase II	Phase III	NDA & Marketed
10 NCEs	DWJ215 Hearing loss	DWP212525 Pemphigus Vulgaris	DWN12088 IPF	DWP16001 Type2 Diabetes		Fexuprazan (NDA) Erosive Esophagitis
	DWJ816S002 Oncology	DWP213338 GvHD		DWP305401# Ulcerative colitis		
	DWJ816S003 Oncology	DWP17061 OA pain				
12 Biologics & 6 Stem cells	HL186 Immuno-oncology	DWP457 Long-acting Insulin	DWP706 Corneal wound	Nabota Square jaw	Nabota Anti-middle of Forehead wrinkle	NABOTA (US/EU) Glabella lines
	HL187 Immuno-oncology	DWP820S001 Dementia	Furestem-RA† Rheumatoid arthritis	Furestem-CD† Crohn's disease	HL036† Dry eye syndrome	
	DWP458 Osteoporosis	DWP820S002 Cerebellar atrophy		HL161* Myasthenia gravis		
		DWP820S006 Severe acute pancreatitis		HL161* Graves's Ophthalmopathy		
	DWP700 Stroke		HL161* WAIHA			





GC Pharma(Former Green Cross Corp.)

www.globalgreencross.com

GC Pharma has been a leading biotech company for developing innovative biotherapies including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.


GC Pharma developed the world's first vaccine against epidemic hemorrhagic fever "Hantavax" and the world's second vaccine for varicella zoster virus vaccine "Suduvax".

GC Pharma is also pursuing opportunities in rare diseases by developing therapies such as Hunterase (world's second ERT for Hunter syndrome). In 2019, GC Pharma's total revenue rose to KRW 1.369 trillion.

Main Products

Product Name / Active Substance	Pharmacological Effects	Exporting Countries	Remarks
1) I.V.-Globulin SN inj. / Human Intravenous Immunoglobulin	A-/Hypogammaglobulinemia Combined therapy with antibiotics for severe bacterial or viral infections Idiopathic thrombocytopenic purpura Guillain-Barre syndrome Kawasaki syndrome	Asia, Middle-East, Central & South America	Plasma Derivatives
2) Albumin inj.-GCC / Human Albumin Solution	For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)	Asia, Middle-East, Central & South America	Plasma Derivatives
3) Green-VIII inj. / Human Blood Coagulation Factor VIII	For the treatment of hemophilia A with supplies of blood coagulation factor VIII	Asia, Middle-East, Central & South America	Plasma Derivatives
4) GreenGene F inj. / Recombinant Coagulation Factor VIII	For the prevention and control of bleeding episodes and preoperative management in hemophilia A	Asia, Middle-East, Central & South America	Recombinant Product
5) Hepabig inj. / Human Hepatitis B Immunoglobulin	For prophylaxis of hepatitis B after exposure to HBsAg For prophylaxis of hepatitis B in neonates	Asia, Middle-East, Central & South America	Plasma Derivatives
6) I.V. Hepabig inj. / Human Hepatitis B Immunoglobulin	For prevention of recurrence of hepatitis B in patients with liver transplants	Asia, Middle-East, Central & South America	Plasma Derivatives
7) Sero-Tet inj. / Human Tetanus Immunoglobulin	For the prophylaxis of tetanus and the reduction of tetanus symptoms	Asia, Middle-East, Central & South America	Plasma Derivatives
8) GCFLU PFS inj. / Split Virion, Trivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Asia, Middle-East, Central & South America	Vaccines
9) GCFLU Quadrivalent PFS inj. / Split Virion, Quadrivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Asia, Middle-East, Central & South America	Vaccines
10) Varicella vaccine-GCC inj. / Live Attenuated Varicella Vaccine	For the prophylaxis against varicella	Asia, Middle-East, Central & South America	Vaccines
11) Hunterase / Idursulfase beta	For treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)	Asia, Middle-East, Central & South America	Recombinant Product
12) Neulapeg PFS Inj. / PEG-GCSF	For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma	Asia, Middle-East, Central & South America	Recombinant Product

R&D Pipeline



CEO
Eun-Chul Huh

Location
107, Ihyeon-ro 30beon-gil,
Giheung-gu, Yongin-si, Gyeonggi-do 16924, Korea

Specialty
1. Plasma Derivatives
2. Vaccine
3. Recombinant protein

Tel / Fax / E-mail
T. 82-31-260-9300
F. 82-31-260-9491

CONTACT US

Technology Transfer / Licensing

Young Seoub Park
BD/General Manager
T. +82-31-260-9417
E. perious@greencross.com

Overseas export

Byung Lim Lee
Overseas Biz/General Manager
T. +82-31-260-9493
E. overseas@greencross.com



Genexine, Inc.

CEO
Young Chul Sung, PhD

Location
700 Daewangpangyo-ro, Korea
Bio ParkBldg. B, Bundang-gu,
Seongnam-si, Gyeonggi-do
13488, Republic of Korea

Specialty
Cancer Immunotherapeutics,
DNA Therapeutic Vaccines,
Next Generation Long-acting
Biologics

Tel / Fax / E-mail
T. 82-31-628-3200
F. 82-31-628-3229
E. bd@genexine.com
ir@genexine.com

Genexine (KOSDAQ, 095700) is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives. hyFc platform and DNA therapeutic vaccine platform are our own core proprietary technologies, which are designed to drive the discovery of a wide range of differentiated therapeutics.

R&D Pipeline

GX-I7 (Long-acting IL-7)

Areas	Indication	Regimen	Non-clinical	Phase 1	Phase 2	Site
	Healthy Volunteers	SAD				KR
Immuno-Oncology	Solid Tumor	Mono				KR
		Mono				CN
		Mono				KR/US
	Glioblastoma	TMZ Combo				US
		Triple Negative Breast Cancer	Pembrolizumab Combo			
	Skin Cancer	Atezolizumab Combo				US

GX-188 (HPV DNA Therapeutic Vaccine)

Indication	Regimen	Non-clinical	Phase 1	Phase 2	Site
Cervical Cancer	Pembrolizumab Combo				KR

GX-H9 (Long-acting hGH)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Adult Growth hormone Deficiency					KR/EU
Pediatric Growth hormone Deficiency					KR/EU

GX-G3 (Long-acting G-CSF)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Neutropenia					KR/EU

GX-E4 (Long-acting EPO)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
CKD-induced Anemia					Mutational Phase 3 on-going ASEAN/AU

GX-G6 (Long-acting GLP-1)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Type 2 Diabetes					EU

GX-G8 (Long-acting GLP-2)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Short Bowel Syndrome					EU

GX-P1 (Long-acting PD-L1)

Indication	Non-clinical	Phase 1	Phase 2	Phase 3	Site
Autoimmune diseases organ transplantation					KR

CONTACT US

Technology Transfer /
Licensing

Taesook Yoon

Business Development / Director
T. +82-31-628-3401
E. taesook.yoon@genexine.com



“The Health Innovator”
as Korea’s leading global total healthcare company.



HANDOK. Inc.

www.handok.co.kr/eng

Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. For more information, please visit www.handok.co.kr.

Main Products

	Product	Indication	Main Export
Endocrine system	Amaryl M, Amaryl MEX	Glimepiride Metformin	Thailand, Dubai, Russia, Hungary, UAE, Philippines, Singapore etc.
	Tenelia M	Teneligliptin, Metformin	-
	Daonil tab.	Glibenclamide	
Integumentary system	Esperson oint. 0.25%	Desoxymethasone Semi-solid	Thailand, Taiwan
Central nervous system	Frisium tab. 10mg	Clobazam	
Cardiovascular system	Lasix tab.	Furosemide	Thailand, Taiwan, Philippines
Osteoarthritis and muscular pain	KETOTOP Plaster	Ketoprofen	Myanmar, Vietnam, Singapore, Kazakhstan, Malaysia etc.

R&D Pipeline

Therapeutic Area	Project	Classification	Indication	Dis.	Pre clinical	Phase I	Phase II	Phase III	Remarks
Orphan	HL2356 (GX-H9)	Biologics	Adult Growth Hormone Deficiency				■		<ul style="list-style-type: none"> Genexine Partnered Supported by Government Funding (KDDF**)
			Pediatric Growth Hormone Deficiency				■		
Oncology	HL5101	Chemical	Cancer		■				<ul style="list-style-type: none"> CMG Pharm. Partnered Supported by NOV***
Ophthalmology	HL3501	Chemical	Glaucoma	■					<ul style="list-style-type: none"> Supported by Government Funding (KDDF**)
Diabetes/ Metabolism	HD-P550	IMD*	Diabetes + Hyperlipidemia		■				
	HD-C715	Chemical	Diabetes	■					
Cardio Vascular	DENEX	Resistant Hypertension	Medical Device				■		<ul style="list-style-type: none"> CE Mark approved (2016yr)
CVD/Infectious Disease	Nanocon RST kit	Medical Device_IVD (IVD: in-vitro Diagnostic)	CVD/Infectious Disease				■		

*IMD: Incrementally Modified Drug

**KDDF: Korea Drug Development Fund

***NOV: National OncoVenture

■ Biologics ■ Small Molecule ■ Medical Device

CEO
Young Jin Kim, Jin Ki Baik

Location
132, Teheran-ro, Gangnam-gu, Seoul, 06235, Korea

Specialty
1. Anti-diabetics New Chemical Entities
2. Anti-diabetics Diabetes Incrementally Modified Drugs
3. Anti-arthritis Plaster

Tel / Fax / E-mail
T. 82-2-527-5114
F. 82-2-527-5001
E. Handok@handok.com

CONTACT US

Technology Transfer / Licensing

SoHyun Kwon
Corporate&Business Development/Senior Vice President
T. +82-2-527-5316
E. sohyun.kwon@handok.com

Overseas export

SoHyun Kwon
Corporate&Business Development/Senior Vice President
T. +82-2-527-5316
E. sohyun.kwon@handok.com

Etc.

Suji Kim
Planning&Coordination Office/ Associate Manager
T. +82-2-527-5329
E. suji.kim@handok.com



Protecting the precious human life from various forms of disease

HANLIM PHARM. CO., LTD.

<http://www.hanlim.com/eng>

CEO
Jae Yoon Kim, Jung Jin Kim

Location
42, Seocho-Daero 52 Gil,
Seocho-Gu, Seoul 06634
Republic of Korea

Specialty
R&D, Manufacturing of API/
BPIs and Pharmaceutical
Product

Tel / Fax / E-mail
T. 82-2-3489-6000
F. 82-2-3489-6101
E. master@hanlim.com

With the corporate mission, "Protecting the precious human life from various forms of diseases", HANLIM has consistently endeavored to improve the health standards of people, and we have become one of the leading pharmaceutical companies in Korea. In 1993, the future-oriented GMP factory was completed together with the founding of the central research center. We continue to make a great investment in accumulating advanced technologies and manufacturing facilities lately to enhance human health.

Main Products

Product Name	Active Ingredient(s)	Category	Remark
T-Sporin Eye Drops	Cyclosporin 0.5mg	Ophthalmic	IMD Product
Nasaflex Nasal Spray	Mometasone furoate 0.5mg, Azelastine HCl 1.4 mg	Allergy&ENT	IMD Product
Risenex Plus Tab.	Sodium Risedronate 35mg, Cholecalciferol 5,600IU	Endocrine	IMD Product
Dages Cap.	Pepsin 25mg, Papain 50mg, Diastase 15mg, Cellulase 15mg, Pancreatin 50mg, Pancrelipase 13mg, UDCA 25mg	Digestive	

R&D Pipeline

Mesenchymal stem cells

Product	Indication	Pre-clinical	Clinical phase		
			1	2	3
HL401	Systemic Lupus Erythematosus	→			

NCE (New Chemical Entity) Discovery

Product	Indication	Pre-clinical	Clinical phase			NDA
			1	2	3	
HL301	Acute Bronchitis	→				
HL217	AMD	→				
HL237	Rheumatoid Arthritis	→				
HL237A	Liver Transplantation	→				

IMD (Incrementally Modified Drug)

Product	Indication	Pre-clinical	Clinical phase			NDA
			1	2	3	
Lumino- mark Inj.	Breast Lesion Surgery Marker	→				
HL-TOF	Rheumatoid Arthritis	→				

CONTACT US

Technology Transfer / Licensing

Mi Jin O
Development Dept /
General Manager
T. +82-2-3489-6166
E. omijin@hanlim.com

Overseas export

Jeonghwa Jenny Yang
Global Business Dept / Director
T. +82-2-3489-6214
E. yjh0717@hanlim.com



Hanmi Pharmaceutical Co., Ltd.

www.hanmipharm.com

Hanmi Pharm is a global pharmaceutical company focused on the development and commercialization of new pharmaceutical products, with presence in Korea and China. The company's R&D efforts focus on three main areas: 1) new biologics based on LAPSCOVERY platform in diabetes, obesity, NASH and rare diseases; 2) novel targeted agents and 3) novel bispecific antibodies based on PENTAMBODY platform for immuno-oncology and targeted therapy. Hanmi has multiple partnerships and strategic collaborations with leading MNCs and Chinese biopharma companies.

Main Products

Category	Product	Use	Ingredient	Exporting countries
Cardiovascular disease	Amosartan	Hypertension	Amlodipine	CIS
	Amosartan Plus	Hypertension	Amlodipine + Losartan + Chlorthalidone	LATAM
	Amosartan Q	Hypertension, dyslipidemia	Amlodipine + Losartan + Rosuvastatin	LATAM
	Rosuzet	Dyslipidemia	Ezetimibe + Rosuvastatin	CIS, LATAM, SEA
	Amodipin	Hypertension	Amlodipine camsylate	-
	Rovelito	Hypertension, dyslipidemia	Irbesartan + Atorvastatin	LATAM
	Carnitil	Alzheimer's disease, dementia	Acetyl-L-carnitine hydrochloride	-
Gastrointestinal disease	Pidogul	Antiplatelet	Clopidogrel napadisilate	MALAYSIA
	Esomezol	GERD, Gastric ulcer	Esomeprazole strontium	-
Urology	Palpal	Erectile dysfunction	Sildenafil	JAPAN
	Gugu	Erectile dysfunction	Tadalafil	JAPAN
Neurology	HANMI TAMS	BPH	Tamsulosin hydrochloride	-
	Naxozol	Anti-inflammatory	Naproxen + Esomeprazole	-
Ophthalmology, etc	Hyalumini eye drop	Artificial tear, Sjögren's syndrome	Sodium hyaluronate	-
	Rabone D	Osteoporosis	Raloxifene + cholecalciferol	-

R&D Pipeline

	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
Obesity/ NASH/ Diabetes	LAP ^S Glucagon Combo HM14320 Obesity/Diabetes/NASH	LAP ^S Triple Agonist HM15211 NASH	LAP ^S GLP/GCG HM12525A Obesity	LAP ^S Exd4 Analog Efeplenatide Diabetes	
	LAP ^S Insulin Combo HM14220 Diabetes	LAP ^S Glucagon Analog HM15136 Obesity			
	LAP ^S Insulin148 HM12480 Diabetes	LAP ^S Insulin HM12460A/HM12470 Diabetes			
Oncology	EZH1/2 Inhibitor Solid tumor	Pan-RAF Inhibitor Belvarafenib Solid tumor	Pan-HER Inhibitor Pozitotinib Solid tumor	Oraxol™ Pacitaxel+encequidar Breast cancer, solid tumor	LAP ^S GCSF Analog Eflapegrastim Neutropenia
	LSD1 Inhibitor SCLC, AML	FLT3 Inhibitor HM43239 AML	Oratecan™ Irinotecan+encequidar Solid tumor		
	ADOR Antagonist Solid tumor	PD-1/HER2 BsAb BH2950 Solid tumor	Oradoxel™ Docetaxel+encequidar Solid tumor		
	GBM Stem Cell Therapy HM21001 Glioblastoma	FLX475 (CCR4 Inhibitor) Solid tumor			
	Immuno-oncology BsAb				
	PD-L1/CD47 BsAb				
Rare Diseases/ Other	LAP ^S ASB HM15450 Mucopolysaccharidosis	LAP ^S Glucagon Analog HM15136 Congenital Hyperinsulinism	LAP ^S hGH Efepegmatropin GH deficiency		
		LAP ^S GLP-2 Analog HM15912 Short Bowel Syndrome	Luminate® Integrin inhibitor DME		
		Luminate® Integrin inhibitor Retinitis Pigmentosa	BTK Inhibitor HM71224 Autoimmune disease		

CEO
Jong-Soo Woo, Se-Chang Kwon

Location
14, Wiryeseong-daero, Songpa-gu, Seoul, 05545, Korea

Specialty
R&D based pharmaceutical products

Tel / Fax / E-mail
T. 82-2-410-9114

CONTACT US

Technology Transfer

James Chung
Global Business Development / Team Leader
T. +82-2-410-9069
E. james.chung@hanmi.co.kr

Licensing

Kyoung Woo Lee
eR&D, Licensing / Team Leader
T. +82-2-410-9291
E. sakshi2@hanmi.co.kr

Overseas export

Steven Cho
Finished products/APIs/
CMO business / Team Leader
T. +82-2-410-0462
E. haamincho@hanmi.co.kr



Helixmith Co., Ltd.

CEO
Sunyoung Kim

Location
21, Magokjungang 8-ro 7-gil,
Gangseo-gu, Seoul 07794,
Korea

Specialty
plasmid DNA-based gene
therapy


Tel / Fax / E-mail
T. 82-2-2102-7100
F. 82-2-887-0011
E. contact@helixmith.com

Founded in 1996, Helixmith has been dedicated to research in gene therapy for over 20 years. Led by Sunyoung Kim and his lab in Seoul National University, the Helixmith team has developed an extremely powerful gene expression system and has tested it in various therapeutic areas. The company is currently headquartered in Seoul, Korea; our clinical development and manufacturing activities are based in San Diego, California in the US. In particular, we co-own a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO in San Diego. Genopis serves both Helixmith and external customers in need of DNA.

Main Products

Product	Target Disease	Technology	Country	Development Stage
VM202	Diabetic peripheral neuropathy	Gene therapy	US	Phase 3 / FDA RMAT
	Diabetic foot ulcer	Gene therapy	US	Phase 3
	Ischemic heart disease	Gene therapy	Korea	Phase 2
Orphan Drug	Amyotrophic lateral sclerosis	Gene therapy	US	Phase 2 / FDA Fast Track
VM206	Breast cancer	DNA vaccine	Korea	Phase 2

R&D Pipeline



CONTACT US

Technology Transfer /
Licensing

Scott Kim
Global Business Development/
Managing Director
T. +82-2-2102-7100
E. contact@helixmith.com



HK inno.N Corporation

As a well-established local pharma in prescription drugs and Health & Beauty, inno.N(Fomer CJHC) is at its preparation for the future by allocating resources to R&D for new drugs, biologics mainly in liver, cancer, and immune disease areas.

In 2019, we launched **K-CAB® Tab. (Tegoprazan)**, a new drug for GERD, as Korea's 30th new drug. K-CAB® Tab. is loved in Korea for its EE, NERD and GU indications, and is expanding into 22 countries including China and Latin America, and is spreading its R&D capabilities to the global market.

Main Products

Product	Indication & Use	Exporting Countries
K-CAB Tab. (Tegoprazan)	Gastroesophageal reflux disease (GERD)	China, Vietnam, Latin America 22 countries including Mexico
Epokine Inj.(rh-EPO)	Anemia of hemodialysis patients with end-stage renal disease	Asia, Latin America and Africa
Vancorin Inj. (Vancomycin)	Serious, life-threatening infections by gram-positive bacteria	Asia
Tapocin Inj. (Teicoplanin)	Serious infections by gram-positive bacteria	Asia
Moveloxin I.V. solution bag (Moxifloxacin)	Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia and so on	Asia
Cinezolid I.V. solution bag (Linezolid)	Vancomycin-resistant Enterococcus faecium infections	-
Citopcin I.V. Solution bag (Ciprofloxacin)	Infections caused by microorganism	Asia
Levotopcin I.V. Solution bag (Levofloxacin)	Infections caused by microorganism	-
Calmtop Inj. (Irinotecan)	Colorectal cancer	-
Pemta Inj. (Pemetrexed)	Pleural mesothelioma and non-small cell lung cancer	-
OmapOne Lipid Inj. bag (Fish/MCT/Soybean/Olive oil)	Supplying energy, essential fatty acids and omega-3 fatty acids to patients.	-
OmapOne Peripheral Inj. bag (Lipid, Amino acid, Glucose)	Supplying Lipid, Amino acid and Glucose to patients	Asia
Atomet XR Tab. (Atorvastatin/Metformin)	Type2 Diabetes/Hyperlipidemia	-
Machkhan Tab. (Candesartan/Amlodipine)	Hypertension	-
CONDITION (Hyaluronic acid)	Anti-hangover drink	China, Japan
HongSamJin Gold (Red Ginseng drink)	Outstanding energy drink produced with 6-year-old red ginseng	China

R&D Pipeline

	Pipeline	Target Indication	DS	PC	Clinical Trial			NDA	MKT	Partnering availability
					PI	PII	PIII			
NCE	IN-A002	Autoimmune disease	██████████	██████████						
	IN-A011	Nutrition	██████████	██████████						
	A2AR inhibitor	Cancer	██████████	██████████						
	FERT inhibitor	Cancer	██████████	██████████						
	DCLK1 inhibitor	Cancer	██████████	██████████						
	HSD inhibitor	NASH	██████████	██████████						
IMD	IN-C008	Hypertension / Hyperlipidemia	██████████	██████████						
	IN-C009	Type 2 Diabetes	██████████	██████████						
	IN-C010	Type 2 Diabetes	██████████	██████████						
	IN-C011	Type 2 Diabetes	██████████	██████████						
	IN-C001	Gastroesophageal reflux disease	██████████	██████████						
Biologicals	IN-B001	Hand, Foot & Mouth Disease	██████████	██████████						
	IN-B002	Smallpox	██████████	██████████						
	Pneumococcal	Pneumonia	██████████	██████████						
	IN-B004	Autoimmune disease	██████████	██████████						
	TANKIO	Cancer	██████████	██████████						

CEO
Seok Hee Kang,
Sang Hyun Yoon

Location
Pine Avenue Tower A, 100,
Euljiro, Jung-gu, Seoul, 04551,
Korea

Specialty
ETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, Gastro Intestinal, Musculoskeletal, Respiratory, Others) & Health functional products

Tel / Fax / E-mail
T. 82-2-6477-0000
F. 82-2-6477-0698
E. HKIN_business@inno-n.com

CONTACT US

Technology Transfer / Licensing

Dr. sun park
Innovation Team /Expert
T. +82-2-6477-0171
E. sun.park@inno-n.com

Overseas export

Mr. Jinho maeng
Global Business/ Manager
T. +82-2-6477-0190
E. jinho.maeng@inno-n.com

Overseas Office

Mr. Sungbin cho
K-CAB BD/ Manager
T. +8180-1249-0427
E. sungbin.cho@inno-n.com

Overseas Office

Mr. Minki Ku
Vietnam branch office/Manager
T. +82-70-4990-2712
E. minki.ku@inno-n.com



HYUNDAI Pharm. Co., Ltd.


www.hyundaipharm.co.kr/english

HYUNDAI Pharm. was founded in 1965 as a pharmaceutical company with the corporate philosophy of "Contributing to the improvement of the health of mankind" based on the philosophy of the CEO who aims at the esteem of human respect and transparent corporate spirit. As a global R&D company, we aim to fulfill our responsibilities for improving public health by focusing on developing new drugs and incrementally modified drugs through continuous investment.

Main Products

Product name	Active ingredients	Indications
Minoxyl - 3%, 5% Solution - 3%, 5% Gel	Minoxidil	Androgenetic alopecia
Minoxyl complex Solution 5%	Minoxidil, Vitamin V6 / E, L-menthol	Androgenetic alopecia
Tenormin Tab.	Atenolol	Hypertension, Angina Pectoris
Uremin Tab.	Desmopressin acetate	Nocturnal enuresis
Mirtapin Tab.	Mirtazapine	Major depressive disorder
Mirap Tab. / ER Tab.	Pramipexole HCl	Parkinson's disease
Hipezil Tab.	Donepezil HCl	Alzheimer's disease
Dimantin Tab.	Memantine HCl	Alzheimer's disease
Tamirin SR Tab.	Galantamine HCl	Alzheimer's disease
Pemirosal Tab. / Dry Syrup	Pemirolast potassium	Bronchial Asthma, Allergic Rhinitis
Surfolase Cap. / CR Tab.	Acebrophylline	Acute & chronic Bronchitis
Levotuss Tab. / Syrup	Levodropropizine	Acute & chronic Bronchitis
Clinium Vaginal Tab.	Dequalinium Chloride	Bacterial & Candida Vaginitis

R&D Pipeline

	CODE	PROJECT	INDICATION	Discovery	Pre-clinical	Phase I	Phase II	Phase III	NDA
NCE	HDNO-1605 [HOB-047]	HD-6277 Novel antidiabetics	Type-2 Diabetes						
	BPDO-1603 [BPS-034]	New fixed-dose combination	Senile disease						
	HDDO-1728	New dosage form	Senile disease						
IMD	HDDO-1756	New fixed-dose combination	Endocrine disease						
	HDDO-1801	New fixed-dose combination	Respiratory disease						

 CEO
Sang-Joon, Lee

 Location
Hyundai Pharm Bldg, Bongeunsa Street 135, Gangnam-Gu, Seoul

 Specialty
 1. NCE - Diabetes
 2. IMD – Fixed dose combination of Alzheimer's disease
 3. IMD – Fixed dose combination of Respiratory disease

 Tel / Fax / E-mail
 T. 82-2-1666-9979
 F. 82-2-2693-7628
 E. jhhwang@hdpharm.co.kr

CONTACT US

Technology Transfer / Licensing

 Byung-Girl, Rhee
 Licensing Team / Team manager
 T. +82-2-2600-3951
 E. bgrhee@hdpharm.co.kr

Overseas export

 Byung-Girl, Rhee
 Licensing Team / Team manager
 T. +82-2-2600-3951
 E. bgrhee@hdpharm.co.kr



Ildong Pharmaceutical Co., Ltd.

CEO
Paul Woong - sup Yun

Location
2, Baumoe-ro 27-gil, Seocho-gu, Seoul, Korea

Specialty
1. Ethical drug/Over-the-counter drug(Vitamins, Probiotics)
2. Antibiotics
3. Anticancer drug

Tel / Fax / E-mail
T. 82-2-526-3114
F. 82-2-526-3030

Since Ildong Pharmaceutical Group was founded in 1941 under the philosophy of 'pharmaceuticals are rooted in humans', we have created and shared significant value for health and prosperity throughout many years and will continue this endeavor. Ildong has become one of the leading pharmaceuticals in South Korea with powerful brand lineups including Aronamin, Biovita, and other major OTC products. We developed robust product pipelines for ethical drugs using our advanced technologies and diverse strategic partnerships.

Main Products

Category	Brand	Features
Ethical drug	Original Brand	Besivo New drug for chronic hepatitis B treatment
		Pirespa Idiopathic pulmonary fibrosis drug
		Flumarin South Korea's widely-used antibiotic
		Sermion Cerebral blood flow enhancer
		Telostop Drug for hypertension and hyperlipidemia treatment(Telmisartan, Rosuvastatin)
	Hypertension complex	Twotops Plus 3-ingredient combination drug for hypertension treatment(Telmisartan, Amlodipine, Hydrochlorothiazide)
		Telostop Plus 3-ingredient combination drug for hypertension and hyperlipidemia treatment (Telmisartan, Amlodipine, Rosuvastatin)
Over-the-counter drug	Generic	Rabiet Gastric acid inhibitor(Rabeprazole)
	Aronamin brand	Aronamin Multivitamin
	Other OTC drug	Exeramine High-content vitamin supplement
Quasi-drug, medical device	Prepain Hemorrhoids treatment(ointment/suppository)	Meditouch Moist wound healing dressing
Health functional food	MyNi	MyNi My nutrition information, health functional food brand
	gQlab	gQlab Patented quadruple-coated probiotics
Beverage	Arogold D	Benefits of sunlight(Vitamin D) in a beverage
Cosmetics	First Lab	A cosmeceutical brand made with Ildong Pharmaceutical's knowhow

CONTACT US

Technology Transfer / Licensing

Young Kyoung Pak
Business Development Team / Manager
T. +82-2-526-3386
E. youngkyoung.pak@ildong.com

Overseas export

Nathan Ahn
Overseas Business Team / Manager
T. +82-2-526-3500
E. any@ildong.com

R&D Pipeline

■ In-house
 ■ In-licensed
 ■ IMD (Fixed dose combination)
 ■ Open Innovation (O.I.)

Type	Indication	MOA	Lab code	Phase					Current Status	Partner(s)
				Preclinical	Phase 1	Phase 2	Phase 3	Approval		
Open Innovation	Solid Tumor	PARP-1* inhibitor	IDX 1197	[Progress bar: Preclinical to Phase 1]					P1 ongoing	National OncoVenture
	PD*	iCp-Parkin	CV-06	[Progress bar: Preclinical]					Preclinical	Cellivory (KOR)
In-house	AMD*	Lucentis biobetters	ID8002	[Progress bar: Preclinical]					Preclinical ongoing	
	Solid Tumor	Avastin biobetters	ID8076	[Progress bar: Preclinical]					Preclinical ongoing	
In-licensed	Acute Migraine	5-HT 1F inhibitor	Lasmiditan	[Progress bar: Phase 1 to Approval]					FDA Approval	Eli Lilly (US)
	CLL*	Rituximab biobetters	TG-1101	[Progress bar: Phase 1 to Approval]					BLA Submission ready	TGTX (US)
IMD (FDC)	Hyperlipidemia	Rosuvastain/Fenofibrate	ID-RF	[Progress bar: Preclinical to Approval]					Pre-registration w/ MFDS*	

* PARP : Poly ADP-ribose polymerase *AMD : Aged related Macular disease * CLL : Chronic lymphocytic leukemia *MFDS : Ministry of Food and Drug Safety * PD: Parkinson's Disease



ISU ABXIS CO., LTD.

www.abxis.com/eng

ISU ABXIS is a biopharmaceutical company founded in 2001 with a desire of being an axis of therapeutic antibody as its names stands for ABXIS = AntiBody + aXIS. Beginning with the successful development and market launch of the Korean first therapeutic antibody Clotinab® in 2007, ISU ABXIS has established its own biotherapeutics development technologies and led Korean biopharmaceutical industry. ISU ABXIS will be dedicated to improving the lives of patients with cancers and incurable diseases.

Main Products



Therapeutic Area	Product	Generic Name	Major Market
Rare Disease	Abcertin®	Imiglucerase	Korea, Iran
	Fabagal®	Agalsidase beta	Korea
Cardiovascular	Clotinab®	Abciximab	Korea, Turkey

R&D Pipeline

Category	Project	Generic Name	Indication	Development Status				
				Discovery	Non-clinical	Phase 1	Phase 2	Phase 3
Novel	ISU104	-	ErbB3 positive cancers (head and neck, etc)	[Progress bar]				
	ISU304	Dalcinonacog alfa	Hemophilia B	[Progress bar]				
Bio-similar	ISU305	Eculizumab	Paroxysmal Nocturnal Hemoglobinuria	[Progress bar]				
	Abcertin®	Imiglucerase	Gaucher's Disease	[Progress bar]				
	ISU106	Nivolumab	Various Cancers	[Progress bar]				

CEO
Seok Joo Lee

Location
Global R&D Center Building
C 5th Fl, 22 Daewangpangyo-ro, 712 Beongil, Bundang-gu, Seongnam-si, Gyeonggi-do 13488

Specialty
1. Novel biological cancer drugs
2. Biosimilars in rare diseases

Tel / Fax / E-mail
T. 82-31-696-4700
F. 82-31-696-4690
E. abxis@isu.co.kr

CONTACT US

Technology Transfer / Licensing

Daniel Yang
Global Commercial Business / Manager
T. +82-31-696-4644
E. danielyang@isu.co.kr

Overseas export

Henry Sung
Global Commercial Business / Manager
T. +82-31-696-4717
E. ezvill@isu.co.kr



Innovative and Responsible

Janssen Korea

www.janssen.com/korea

CEO
Jenny Zheng, Lee Jung-Hee

Location
25F LS-Yongsan Tower, 92
Hangangdaero, Yongsan-gu,
Seoul, Korea

Specialty

1. Oncology new drug – small & large molecules, advanced therapy
2. Autoimmune disease new drug – small & large molecules
3. Infectious Disease chemical new drug & Vaccine biological new drug

Tel / Fax / E-mail
T. 82-2-2094-4500
F. 82-2-2094-4570
E. hsh2@its.jnj.com

Janssen Korea, the Korean branch of the pharmaceutical division of Johnson & Johnson, started as a joint company with Yuhan Corporation in 1983. For the last 30 years, it has been committed to provide useful medicines for the treatment of diverse diseases.

We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Main Products

Therapeutic Area	Product	Ingredient	Indication
Neuroscience	Invega Sustenna	Paliperidone palmitate	Schizophrenia
	Invega Trinza	Paliperidone palmitate	Schizophrenia
Oncology	Velcade	Bortezomib	Multiple Myeloma, Mantle Cell Lymphoma
	Darzalex	Daratumumab	Multiple Myeloma
	Imbruvica	Ibrutinib	Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
	Zytiga	Abiraterone acetate	Metastatic Castration-Resistant Prostate Cancer
Infectious Disease	Sirturo	Bedaquiline	Multi-Drug Resistant Tuberculosis
Pulmonary Hypertension	Opsumit	Macitentan	Pulmonary Hypertension
Pain	Ultracet	Tramadol	Moderate to severe Pain
	Nucynta	Tapentadol	Severe Pain
Immunology	Simponi	Golimumab	Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
	Remicade	Infliximab	Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis
	Stelara	Ustekinumab	Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis
	Tremfya	Guselkumab	Psoriasis

R&D Pipeline

TA	Project/Product	Indication	Progress in Phase 2	Progress in Phase 3
Immunology	TREMFYA®	Psoriatic arthritis, Crohn's Disease		✓
	SIMPONI®	Pediatric Ulcerative Colitis		✓
	STELARA®	Lupus		✓
Oncology	erdafitinib	Non-muscle Invasive Bladder Cancer (NMIBC)	✓	
	apalutamide	Prostate cancer		✓
	niraparib	L3 Prostate cancer metastatic castration-resistant	✓	
	Lazertinib / JNJ-6372	Non Small Cell Lung Cancer	✓	
	BCMA CAR-T	Relapsed refractory multiple myeloma, genetic engineered cell therapy	✓	
Neuroscience	SPRAVATO®	Major depressive disorder at imminent risk for suicide		✓
	ponesimod	Multiple sclerosis		✓
	pimodivir (JNJ-3872)	Influenza A		✓
Infectious Disease	VAC52150	Monovalent Ebola Virus Vaccine		✓
	VAC89220	HIV Prevention Vaccine		✓
Pulmonary Hypertension	OPSUMIT®	Aged ≥2 to <18 years with Pulmonary Arterial Hypertension, Chronic thromboembolic pulmonary hypertension		✓
	UPTRAVI®	Chronic thromboembolic pulmonary hypertension		✓

CONTACT US

Technology Transfer / Licensing

Lee, JoonYup
MESO / Biz Innovation Lead
T. +82-10-8928-5651
E. jlee61@its.jnj.com



JW Pharmaceutical

www.jw-pharma.co.kr/pharma/en/main.jsp

JW group Provides pharmaceuticals vital for maintaining the lives of patients such as anticancer drugs and antibiotics, and has developed into a leading pharmaceutical company and global manufacturer of I.V. Solutions.

For 75 Years ever since its foundation in 1945, JW group focuses on healthcare, ETC, OTC, diagnostics and medical equipment. Based on new technologies and services for healthy lives of human beings, JW group has built up strong sales network across the country and superior pipelines in I.V. solutions, antibiotics, oncology, cardiology, rheumatology and gout.

Main Products

1. Finished Product

- Carbapenem Antibiotics
- General I.V Solutions & Other Sterile Solutions
- Antimicrobial & Antifungal Agents
- Topical
- Agents for Antibiotics
- Amino Acid Solutions
- Gastrointestinal Agents
- Multivitamins
- Miscellaneous

2. API (Active Pharmaceutical Ingredient)

- Carbapenem Antibiotics: Imipenem/Cilastatin
- Anti-fungals: Ketoconazole, Itraconazole, Fluconazole
- Chiral Products for Custom Synthesis & Specialty Amino Acid
- Miscellaneous

R&D Pipeline

	Preclinical		Phase 1	Phase 2	Phase 3	Registration
Oncology	Project A1 WNT inhibitor	Project B1	CWP291 WNT inhibitor			
	Project B2	Project B3		CreaVax-BC GBM*	CreaVax-HCC HCC*	CreaVax-RCC RCC*
	Project B4					
Immune diseases	Project A2 WNT inhibitor	Project B5	JWP1601 H4R antagonist	URC102 Anti-gout		
Cardiovascular and Metabolic diseases						LIVALO
					LIVALO E	LIVALO V
						J-DART
Regenerative medicine	CWL080061	Project A3 WNT activator				
Orphan	Project A4 WNT activator			HEMLIBRA Hemophilia		
Eye diseases	Project A5 H4R antagonist					

*GBM : glioblastoma multiforme *HCC : Hepatocellular carcinoma *RCC : Renal Cell Carcinoma

CEO
SHIN YOUNG SUB,
LEE SEUNG RYLL

Location
2477, Nambusunhwan-ro,
Seocho-gu, Seoul, 06725,
Korea

Specialty
I.V-solutions, antibiotic,
cardiovascular, urology, gas-
trointestinal, nephrology and
anticancer

Tel / Fax / E-mail
T. 82-2-840-6777
F. 82-2-831-8351

CONTACT US

Technology Transfer / Licensing

Jiseon Lim
Licensing/Manager
T. +82-2-840-6883
E. jiseon_lim@jw-pharma.co.kr

Overseas export

Jungoo Lee
Global Sales/Director
T. +82-2-840-6718
E. jimmy@jw-holdings.co.kr

Etc.

Yeobin Yun
Management Planning/ Manager
T. +82-2-840-6658
E. 20111556@jw-group.co.kr



The best beyond the first

KOLMAR KOREA

www.kolmar.co.kr/eng/

CEO
Ho Kyoung Lee

Location
245, Sandan-gil, Jeonui-myeon,
Sejong, 30003, Korea

Specialty
1. First generic and incrementally modified drug
2. PreMix Injection
3. Topical (ex. Nail Lacquer)

Tel / Fax / E-mail
T. 82-2-515-0150

Since its establishment in 2002, Kolmar Korea offers one-stop CMO service. Our facility is KGMP certified (PIC/S GMP) with excellent capacity and quality management. Kolmar is one of the leading CMO companies, equipped to produce all dosage forms, for diverse indications based on R&D capacity. Innovative Lid-cap (Liquid filling in hard capsules) product is representative item of our one and only technique. With unique strength, Kolmar is broadening the scope to Worldwide beyond Korean market.

Main Products

Indication	Product Name	API	Main Market
Circulatory /Cardiovascular	Hiforge Tab	Valsartan, Amlodipine	HongKong
	Telopin Tab	Telmisartan, Amlodipine	
	Lipar Tab	Atorvastatin	HongKong
Endocrine System	Febuxt Tab	Febuxostat	Macau, Cambodia
Gastro-Intestinal	Nexpesol Tab	Esomeprazole	HongKong, Macau
NSAIDS	Painless Tab	Acetaminophen, Tramadol HCl	
	Celecoxib Cap	Celecoxib	HongKong
Respiratory	Pelium Syrup, Tab	Pelagonium Sidoides	Georgia
Dermatologicals	Ciclopirox Nail lacquer	Ciclopirox	Peru
	Prosol Ointment, Lition	Clobetasol Propionate	Cambodia
Infusion	Para-K	Acetaminophen	
	Suppramin	Amino acid	
Lid-cap (LiquidinHardcap)	Colin-K Lidcap	Choline alfoscerate	

Dosage Form	Description
Oral Solids	Tablet, Hard Capsule, Powder
Sterile	Injection (ampoule), Infusion, Eye drops, Lyophilized Injectables
Oral solutions	Syrup, Suspension
Topical	Ointment, Cream, Lotion, Solution, Nail Lacquer
Quasi Drug	Toothpaste, Gargle, Sanitizer
Lid-cap	Liquid filling in Hard Capsules (Innovative tech of Kolmar)

CONTACT US

Technology Transfer /
Licensing

Yun-jung Joo
Pharmaceutical Development
Dept. / Director, Pharmacist
T. +82-2-3459-5461
E. yjjoo@kolmar.co.kr

Overseas export

Sun A, Ryu
Overseas Pharmaceutical Business
team / Senior Manager
T. +82-2-3459-5450
E. elena@kolmar.co.kr

Etc.

Seong-Ki Lee
Planning & Management Team/
General Manager
T. +82-2-3459-5413
E. earthkeeper@kolmar.co.kr

R&D Pipeline

Project	Drug	Indication	Product development					
			Research	Preclinical	PI	PII	PIII	Market
New Drug	KKM-162	inflammatory bowel disease	██████████					
	NDR-171(Herbal)	atopic dermatitis	██████████					
	NDR-171(Chemical)	atopic dermatitis	██████████					
	NDR-172	antitussive expectorants	██████████					
Incrementally modified drug	KKM-174-A	diabetes	██████████	██████████				
	KKM-174-C	diabetes	██████████	██████████				
	KKM-174-D	diabetes	██████████	██████████				
	KKM-181-A	hypertension	██████████	██████████				
	KKM-181-C	hypertension	██████████	██████████				
	KKM-183-A	antithrombotic	██████████	██████████				
	KKM-184-A	diabetes	██████████	██████████	██████████			
	KKM-184-D	diabetes	██████████	██████████	██████████			
KKM-186-C	hypertension	██████████	██████████	██████████				
KKM-191-D	diabetes	██████████	██████████					



Korea Otsuka Pharmaceutical Co., Ltd.

www.otsuka.co.kr/introduction_en

Korea Otsuka Pharmaceutical supplies excellent and innovative pharmaceutical and healthcare products. At a multinational pharmaceutical company equipped with large-scale production facilities in Korea, we contribute to the growth of national economy through domestic production as well as export. With understanding of customers, markets and social responsibilities, we are fulfilling our role and mission to become a company contributing to the healthy life of Koreans.

Main Products

Category	Product	Generic name	Export
CNS	Abilify Tab	Aripiprazole	EU, Hong Kong, Thailand, Indonesia, Philippine
	Abilify OD Tab		
	Abilify Maintena Inj		
CV	Pletaal Tab	Cilostazol	Japan, China, Indonesia
	Pletaal SR Cap		
	Samsca Tab	Tolvaptan	Thailand, Philippine, Indonesia, Vietnam
GI	Mucosta Tab	Rebamipide	Japan, China, Indonesia
ONC	Busulfex vial	Busufan	
	Iclusig Tab	Ponatinib	
PUL	Delyba Tab	Delamanid	

R&D Pipeline

TA	Product	indication	Development						
			Discovery	Preclinical	Phase1	Phase2	Phase3	Launch	
Orphan	Delyba Tab	Multi-drug resistant tuberculosis							
	Iclusig Tab	CML, Ph+ ALL							
New drug	OPB-111077	Cancer							
	OPS-2071	Intestinal infection							
	OCV-501	Cancer							
	ASC-01	Schizophrenia							
	SGL-110-04,06,07,12	AML							
	TEV-48125	Episodic migraine, Chronic migraine							
	Rexulti	Schizophrenia, Pediatric							
	Abilify Maintena Inj	Schizophrenia							
	Samsca Tab	Hyponatremia, ADPKD							
	Incrementally Modified Drug	Pletaal SR Cap	Cerebral infarction						
Abilify OD Tab		Schizophrenia							
Mucosta SR Tab		Gastritis							
Medical Device	Paradise	Resistant hypertension							

CEO
Moon, Sung-ho

Location
(06227) 226, Yeoksam-ro,
Gangnam-gu, Seoul, Republic
of Korea

Specialty
1. Chemical drug of CNS category
2. Chemical drug of Oncology category
3. Orphan drugs & First in class products

Tel / Fax / E-mail
T. 82-2-3287-9000
F. 82-2-3287-9069
E. otsuka@otsuka.co.kr

CONTACT US

Technology Transfer / Licensing

Lee sang wook
Market Access Team/Team Leader
T. +82-2-3287-9150
E. hufs91@otsuka.co.kr

Overseas export

Heo won nyong
Resource Management Team/
Team Leader
T. +82-2-3287-9060
E. tank@otsuka.co.kr



For the Best Global Pharmaceutical Company

Korea United Pharm, Inc.

www.kup.co.kr

CEO
 DUK YOUNG KANG

Location
 Seoul, Gangnam-gu, Nonhyeon-ro 121street 22

Specialty
 Incrementally Modified Drugs for
 1. Antithrombotic
 2. Gastrointestinal
 3. Respiratory disease

Tel / Fax / E-mail
 T. 82-2-512-9981
 F. 82-2-548-4599
 E. webmaster@kup.co.kr

CONTACT US

Technology Transfer / Licensing

Kitae Kim
 BD Licensing / Section Manager
 T. +82-2-558-8612(223)
 E. withkt@kup.co.kr

Overseas export

Hans Cho
 Overseas Business / General Manager
 T. +82-2-543-4079
 E. hanscho@kup.co.kr

Overseas Office

Jae Hyeok Choi
 Overseas Marketing / Assistant Manager
 T. +82-2-512-9982
 E. joyful0710@kup.co.kr

Etc.

JUNGWOOK LEE
 Public Relations / Assistant Manager
 T. +82-2-512-9981
 E. imurmvp@kup.co.kr

Since its establishment in 1987, Korea United Pharm has continued to develop various products through prestigious R&D investment. Korea United Pharm has been nominated as one of the "Asia's 200 Best under a Billion" by Forbes for two consecutive years. It has established several overseas branches and corporations to make inroads into the global market. Also, it is striving to do the best to fulfill social responsibilities through various social contribution activities.

Main Products

Product	Active ingredient	Indication
Clanza CR Tab	Aceclofenac	anti-inflammatory
Clavixin Duo Cap.	Clopidogrel + Aspirin	antithrombotic
Cilostan CR Tab.	Cilostazol	antithrombotic
Gastin CR Tab.	Mosapride	functional dyspepsia
Levotics CR Tab.	Levodropropizine	bronchitis
Unigril CR Tab.	Sarpogrelate HCl	antithrombotic
Fenorics EH Tab.	Fenofibric acid	hyperlipidemia
Kalomin S Tab.	Pelargonium sidoides	bronchitis
Glicetil Syrup	Choline alfoscerate	brain functioning
Omethyl Cutilet Soft Cap.	Omega-3-acids ethyl esters 90	hyperlipidemia

R&D Pipeline

TA	Project	Indication	Category	Discovery	Preclinical	Phase I	Phase II	Phase III	Remarks
Respiratory disease	UI009 UI010	Asthma, COPD		██████████					
Metabolic disorders	UI018	Hypertriglyceridemia		██					
Hematological disease	UI022 UI023	Pheripheral arterial disease		██					
Respiratory disease	UI026	Acute respiratory disease		██					
Gastrointestinal disease	UI028	Functional dyspepsia	IMD	██					
Hematological disease	UI036	Nonvalvularatrial fibrillation		██████████					
Gastrointestinal disease	UI058	Gastroesophageal reflux disease		██████████					
Metabolic disorders	UI061	Hyperlipidemia		██████████					
Inflammatory disease	UI063	Antipyretic		██					



Kuhnil Pharmaceutical Co., Ltd

www.kuhnil.com/english

Under a vision of being a Global pharmaceutical company contributing to improving quality of life, Kuhnil continues to become an unique research focused global company, through development of new drugs, innovative global biopharmaceuticals, DDS and combinations drug products in an effort to improve quality of life in patients. In 2019, Kuhnil received EU GMP certification of the ROSUMEGA and approved the European final product, and Kuhnil has received sales approval of Circadin. And Kuhnil will be lunched a *Daptomycin*.

Main Products

Field	Product	Content	Major Export Country
Cardio Vascular	Omacor Cap	Omega-3-acid ethyl esters	
	Rosumega Cap	Omega-3-acid ethyl esters, Rosuvastatin	Italy, Mongolia
	Experid Pow	Deferasirox	
Central Nervous system	Circadin Tab	Melatonin	
Respiratory	Pulmican Respule	Budesonide micronized	
	Formerol Dry syr.	Formoterol fumarate	
Musculoskeletal Disorders	Lodine kuhnil Cap/Tab /SR Tab	Etodolac Micronized	
Gastrointestinal	Wellcon Tab.	Calcium polycarbophil	
	Bioflor 250 Pow	Saccharomyces boulardii	
	RasB Tab, RasBD Tab	Potassium bismuth citrate, Panitidine hydrochloride, Sucralfate hydrate	
Infectious Disease	Amocla Duo Tab/Syr/inj	Amoxicillin, Potassium clavulanate	

R&D Pipeline

Product	Indication	Research	Preclinical	Phase I / PK	Phase I	Phase I	Launch
KI 1101	Hyperlipidemia						
KI 1102	Hyperlipidemia						
KI 1107	Hyperlipidemia						Market
KI 1114	Hyperlipidemia						Under registration
KI 3101	Hyperlipidemia						Market
KI 3106	Hyperlipidemia						
KI 1120	Female Hypoactive Sexual Desire Disorder						
KI 1121	Hyperlipidemia						
KI 1122	Hyperlipidemia						
KI 1123	Obesity						
KI 1128	Female Hypoactive Sexual Desire Disorder						
KI 1129	Dietary disorders						
KI 1130	NASH						
KI 3110	Intestinal disorders						Under registration
KI 3117	chronic renal failure, Osteoporosis						
KI 1115	Anticoagulant						Market

CEO
Kim Young Joong

Location
OhSong B/D, 14, Jeongdong-gil, Jung-gu, Seoul, Korea, 100-120

Specialty
1. New drug
2. Innovative global biopharmaceuticals
3. DDS pharmaceuticals

Tel / Fax / E-mail
T. 82-2-714-0091
F. 82-2-719-0493
E. kuhnil@kuhnil.com

CONTACT US

Technology Transfer / Licensing

Hankuk Lee
BD team
T. +82-2-2175-9750
E. hkleee@kuhnil.com

Overseas export

Seulgi Bang
Overseas team
T. +82-2-2715-9722
E. sgbang@kuhnil.com



LG Chem, Ltd

CEO
Hak Cheol Shin

Location
LG Twin Towers, 128, Yeouidaero, Yeongdeungpo-gu, Seoul, South Korea

Specialty
Small molecules/biologics-based new medicine in oncology and immunology, Small molecules/biologics-based new medicine for diabetes and metabolic disease, Vaccine

Tel / Fax / E-mail
T. 82-2-3773-1114
F. 82-2-3773-7813
E. webmaster@kup.co.kr

Based on our superior biotechnology and R&D capabilities accumulated since 1980s, we have been successful in developing a variety of original products including Korea's first growth hormone for children, new drugs for diabetes, etc. We are actively moving beyond the domestic market into overseas markets, and with continued investment and R&D reinforcement, we are expanding the pipeline for new drug development and pushing to become a global pharmaceutical corporation.

Main Products

Products	Description
Zemiglo®/Zemimet®	The optimized DPP-4 inhibitor having potent efficacy, reliable safety and better compliance benefits/Once daily DPP-IV inhibitor and Metformin SR combination product
Eucept®	The first biosimilar of Etanercept ever developed by LG Chem.
Eutropin®	The right choice for managing short stature recombinant human growth hormone with proven efficacy and safety since 1993
Eupenta®	Combined Diphtheria, Tetanus, whole cell Pertussis, Hepatitis B and Haemophilus influenzae type B. Eupenta can prevent five different childhood disease with a single injection
YVOIRE®	Cross-linked sodium hyaluronate made by microbial fermentation for tissue augmentation and wrinkle correction

R&D Pipeline

Field	Projects	Indication	Discovery	Preclinical	Clinical Trial		
					Phase I	Phase II	Phase III
Vaccine	LR19114	DTP/HepB/Hib/IPV prevention				●	
	LR19113	Poliomyelitis prevention					●
Biologics	LBAL	Autoimmune disease					●
	CUE101	HNSCC			●		
	PDC-lung-101	NSCLC			●		
	LR19156 (Undisclosed)	Obesity		●			
	Stem Cell therapy		●				
	LR19129 (CUE-102/103)	Cancer	●				
Chemicals	DPP4-i + SGLT2	Diabetes					●
	S1P1	Ulcerative colitis				●	
	Xanthine Oxidase	Gout				●	
	LR19021(MC4R)	Obesity		●			
	LR19123 (GPR120)	Diabetes		●			
	LR19018 (Undisclosed)	NASH		●			
	LR19024 (Undisclosed)	OA		●			
	LR19XXX (Undisclosed)	Cancer		●			
LR19XXX (Undisclosed)	Cancer		●				

CONTACT US

Technology Transfer / Licensing

Jong Heon Won
Business Development Team / Manager
T. +82-2-6987-4072
E. jayden@lgchem.com



Medytox Inc.

www.medytox.com/?site_id=en

As the first botulinum toxin product developer in Korea, we feel pride and responsibility for this industry. Which is why we pursue to improve the transparency and the competitiveness of Korea's biopharmaceutical businesses by implementing of more scientific guidelines for industry practice.

Aiming to become a top global biopharmaceutical company. We plan to expand into the leading pharmaceutical markets and emerging markets. Ceaselessly conducting new research to introduce a new type of botulinum toxin product to the world market.

Main Products



Product	Ingredient	Characteristic
Neuronox®	Clostridium botulinum toxin type A (Hall strain)	- Representative brand of Medytox Inc. which is registered in 33 countries. - Neuronox® has ranked No.1 selling product in Korean market, and also in Japan, Thailand.
Innotox®	Clostridium botulinum toxin type A (Hall strain)	- The world's first liquid type botulinum toxin type A product. - Excluded the dilution process in using botulinum toxin product improving convenience of treatment and accuracy of dose. - Enhanced safety from excluding animal derivatives and HSA from the final product.
Coretox®	Clostridium botulinum toxin type A (150kDa) (Hall strain)	- An advanced new botulinum toxin type A product contains pure neurotoxin, excluding all non-toxin proteins from its ingredients. - Prevents users from gaining immunity by antibody formation which wear down the effects of botulinum toxin. - Enhanced safety from excluding animal derivatives and HSA from the final product.

R&D Pipeline

Division	Code	Indication	Stage
Biodrug	Neuronox®	Benign Masseteric Hypertrophy, Overactive Bladder, Migraine, Glabellar Line(US, EU, China, Taiwan, Russia), Lateral Canthal Line(US, EU), Blepharospasm(China)	Approved + clinical
	Innotox®	Aesthetic and Treatment (US, EU)	Approved + Clinical
	Coretox®	Upperlimb Spasticity	Approved + Clinical
	MT912	Macular Degeneration	Preclinical
	MT927	Immune Disorder	Discovery
	MT971	Inflammatory Bowel Disease	Discovery
	MT981	Solid cancers	Discovery
Synthetic Drugs	MT921	Fat Reduction	Clinical

CEO
Jung Hyun Ho

Location
78, Gangni 1-gil, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea

Specialty
Botulinum toxin products, Medical aesthetics, Bio-pharmaceuticals

Tel / Fax / E-mail
T. 82-2-6901-5880
F. 82-2-3476-8372

CONTACT US

Technology Transfer / Licensing

Kim Junghwan
Business Development Team/ Manager
T. +82-2-6901-5839
E. junghwan.kim@medytox.com

Overseas export

Hong Kwanghee
International Business Team/ Director
T. +82-2-6901-5430
E. khhong@medytox.com

Overseas Office

Park Yeongsang
Northeast Asia Biz Team/Director
T. +82-2-6901-5875
E. yspark@medytox.com



Pharam Research Products

CEO
Ki-Seock Kang, Thin-Kyu Kim

Location
77-19, Gwahakdanji-ro, Gang-neung-si, Gangwon-do, Korea

Specialty
1. Regenerative and immuno-stimulative medicine
2. Advanced medicine to improve QOL(Quality of life)

Tel / Fax / E-mail
T. 82-31-8039-1500
F. 82-31-8039-1501

PharmaResearchProducts has been researching and developing healthcare products for anti-aging and improving Quality of Life. In 2007, PharmaResearchProducts stood up as a leading regenerative medicine company by developing endogenous repair stimulator PDRN®. Moreover, PharmaResearchProducts diversified the product pipelines for regenerative medicine from on license-in, co-developments to strategic investments. PharmaResearch Products is promoting market expansion in both domestic and global.

Main Products



Category	Product name	Use
Drug	Re-an eye drop	Cornea and conjunctiva regenerative eye drop
	Rejuvenex Injction	Wound healing and tissue regenerative injection
Medical Device	Rejuran	New Regenerative Filler (Healer) for Satisfying both skin regeneration and filler effect
	Conjuran	Intra-articular injection for Cartilage regenerative osteoarthritis treatment

R&D Pipeline

Project	2019	2020	2021	2022
Tendinopathy		IND	Clinical Study (Phase 3)	Approval
Atopy medicines		IND	Clinical Study	Approval
Dry eye syndromes	Pre-review	Approval		
PXL01(Global)	IND		Clinical study (Phase 3)	Approval in Europe
PXL01(Domestic)		IND	Clinical study	Approval
LL-37	Clinical study (Phase 2)		Licensing out	
PDRN New Formulation	Non-Clinical Study	IND	Clinical Study	Clinical Study (Phase 3)
Zadaxin New Formulation	Non-Clinical Study	IND	Clinical Study (Phase 1)	Clinical Study (Phase 2)



Pharmicell Co., Ltd.

www.pharmicell.com/eng

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy (Hearticellgram-AMI) in 2011. The company's business area divided into two sectors as below in detail.

First, in the bio business sector, stem cell R&D for curing obstinate disease and improving human health. Second, the biochemical division develops and produces Raw Material Pharmaceutical Intermediates.


Pharmicell Co., Ltd. will do its best to grow into a respected company for curing obstinate disease and improving human health.

Main Products



Product (Ingredient/Formulation)	Use	Remarks
Hearticellgram-AMI (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Acute Myocardial Infarction	Launched
Cellgram-LC (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Alcoholic Liver cirrhosis	Developing (Clinical Trial, Phase II completed)
Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cell)	Erectile Dysfunction	Developing (Clinical Trial, Phase I completed)
Cellgram-DC-OC (Prostate Cancer Ag pulsed Autologous Dendritic Cell)	AnticancerImmuncell Therapeutic Vaccine for Prostate Cancer.	Developing (Clinical Trails)
Cellgram-DC-OC (Ovarian Cancer Ag pulsed Autologous Dendritic Cell)	AnticancerImmuncell Therapeutic Vaccine for Ovarian Cancer.	Developing (Clinical Trails)

R&D Pipeline



CEO
Kim, Hyun Soo

Location
7th floor, Ssangbong Building,
874 Unju-ro, Gangnam-gu,
Seoul-si

Specialty
1. Stem Cell Therapeutics
2. Next Generation Dendritic Cell Therapeutic Vaccines
3. Raw Material Pharmaceutical Intermediates

Tel / Fax / E-mail
T. 82-2-3496-0114
F. 82-2-3496-0159
E. pmc@pharmicell.com

CONTACT US

Technology Transfer /
Licensing
Overseas export
Overseas Office
Etc.

DongHuk Jang
Planning & Coordination Dept./
Manager
T. +82-10-4056-5753
E. dhjang@Pharmicell.com



FOR THE HEALTHY LIFE & FRUITFUL FUTURE

Samjin Pharmaceutical Co., Ltd.

www.samjinpharm.co.kr/front/en/main/index.asp

CEO
Hong Soon Jang, Yong Ju Choi

Location
121, Wausan-ro, Mapo-gu,
Seoul 04054 Rep. of Korea

Specialty
Manufacture, Marketing and
Distribution of Pharmaceutical
Product (FDF and API)

Tel / Fax / E-mail
T. 82-2-3140-0700
F. 82-2-392-5312

Samjin is a pharmaceutical company striving to produce novel therapeutics with relentless efforts. Since 1968, Samjin has developed steady sellers including antithrombotics, antihyperlipidemics, and NSAIDs, and has been developing novel therapeutics to address high unmet medical needs in the field of ophthalmology, oncology, fibrosis, and neurology. Samjin has established strategic partnerships with 20 profit/non-profit organizations to accelerate innovative drug development and is actively seeking for global partnerships via open innovation.

Main Products

Category	Products	Indication	WWS
FDF	Plateless Tablet (Clopidogrelbisulfate)	Antithrombotic	
	Geworin Tablet (Acetaminophen, etc)	NSAIDs	Philippine, Uzbekistan
	Neustatin-R Tablet (Rosuvastatin calcium)	Antihyperlipidemia	Hongkong, Iraq
	Hanomycin Injection (Vancomycin hydrochloride)	Antibiotics	Philippine, Dominica Rep., Vietnam
	Neurocava PG Capsule (Pregabalin)	Anticonvulsants	Philippine, Ecuador, Iraq
	Nemeol Tablet (Esomeprazole)	Proton Pump Inhibitors	Hongkong
API	Clopidogrel Bisulfate (Form I & Form II)	Antithrombotic	Indonesia, Egypt
	Rosuvastatin calcium	Antihyperlipidemia	Indonesia
	Apixaban	Anticoagulants	

R&D Pipeline

	Code	Indication	Development Stage	Route of Administration
NCE	SA001 (Rebamipide mofetil)	Dry eye syndrome, Sjogren syndrome	Clinical Phase II	Oral
	SJP1803/1804 (NOX inhibitor, APX-1004F)	Macular degeneration	Preclinical	Eye drop, Implant for long-term delivery
	SJP1601 (pan-RAF inhibitor)	Cancer	Preclinical	Oral
	SJP1602 (FAK/Pyk2 dual inhibitor)	Cancer (TNBC)	Preclinical	Oral
	SJP1604 (APTA-DC, APTA-16)	Cancer (Resistant AML/MDS)	Preclinical	Injection
	SJP1901	Cancer, Fibrosis	Biological Testing	-
	SJP1902	Cancer immunotherapy	Biological Testing	-
	SJP1801	Alzheimer's disease, Parkinson's disease	Biological Testing	Oral
IMD	SJP003	Diabetes	Clinical	Oral
	SJP006	Anti-viral	Biological testing	Oral

CONTACT US

Technology Transfer / Licensing

Jang Hyun Lee
Medicinal Chemistry Lab. /
Senior Scientist
T. +82-31-8039-8871
E. janghlee@samjinpharm.co.kr

Overseas export

Shin Koo Kang
Overseas Biz / Team Manager
T. +82-2-3410-0728
E. skkang@samjinpharm.co.kr



Samyang Biopharmaceuticals Corporation

www.samyangbiopharm.com/eng

Samyang Biopharm is specialized in development of small-molecule drugs, new biologic drugs and virus vaccines and commercialization of DDS-based modified drugs and first generics for cancer treatment. Samyang Biopharm is exporting its oncology products and expands its product portfolio. Samyang's cytotoxic facility obtained GMP certifications from KR, EU, and JP. The new facility is expected to achieve full cGMP operation. Samyang Biopharm USA Inc. in Cambridge concentrates on global new drug development in immune-oncology and rare diseases.

Main Products

FDI	Product	Formulation	Strength	Specifications
Polymeric Micelle	Genoxel [®] PM	Lyophilized Injection	30mg, 100mg/vial	In-house
	Nanoxel [®] M	Lyophilized Injection	20mg, 80mg/vial	In-house
Generics for Solid Tumors	Paclitaxel	Liquid Injection	30mg, 100mg, 150mg, 300mg/vial	USP, EP
	Docetaxel	Liquid Injection	20mg, 80mg, 140mg, 160mg/vial	EP
	Oxaliplatin	Liquid Injection	50mg, 100mg, 200mg/vial	EP, JP
	Gemcitabine	Liquid Injection	200mg, 1g/vial	USP
	Pemetrexed	Liquid Injection	1g/vial	In-house
		Liquid Injection	100mg, 500mg/vial	In-house
Generics for Blood Cancers	Everolimus	Lyophilized Injection	100mg, 500mg/vial	In-house
	Azacitidine	Oral Tablet	2.5mg, 5mg, 10mg/pk	In-house
	Decitabine	Lyophilized Injection	100mg, 150mg/vial	In-house
	Bortezomib	Liquid Injection	40mg, 50mg/vial	In-house
	Bendamustine	Lyophilized Injection	2.5mg, 3.5mg/vial	In-house
Generis for Supportive Care	Lenalidomide	Liquid Injection	25mg, 100mg/vial	USP
	Palonosetron	Oral Tablet	2.5mg, 5mg, 10mg, 15mg, 20mg, 25mg/pk	KP
	Zoledronic Acid	Liquid Injection	0.075mg, 0.25mg, 0.4mg/vial	KP
Transdermal Drug Delivery System	Diclofenac	Plaster	4mg/vial	KP
	Nicotine	Patch	120mg	BP
		Gum	14mg, 28mg, 42mg	EP
	Fentanyl	Patch	2mg	USP
	Rivastigmine	Patch	12µg/h, 25µg/h, 50µg/h, 100µg/h	EP
	Tulobuterol	Patch	6mg(4.6mg/24hr), 12mg(9.5mg/24hr)	EP
	Nitroglycerin	Patch	0.5mg, 1mg, 2mg	In-house
			22.4mg(0.2mg/hr)	USP

API	Product	Package	DMF
Cytotoxic APIs	Paclitaxel	Up to 500 g	US DMF, CEP, KDMF
	Docetaxel	Up to 500 g	US DMF, CEP
	Pemetrexed	Up to 500 g	KDMF
	Bortezomib	Up to 500 g	KDMF
	Cabazitaxel	Up to 500 g	-

R&D Pipeline

Country	Technology	Research	Clinical	Registration	
Korea	PM	Paclitaxel	████████████████████	████████████████████	████████████████████
		Docetaxel	████████████████████	████████████████████	████████████████████
		SYP-1261	████████████████████	████████████████████	████████████████████
	PNP	SYP-0709	████████████████████	████████████████████	████████████████████
		SYP-0709S	████████████████████	████████████████████	████████████████████
	SEMP	SYO-1906	████████████████████	████████████████████	████████████████████
	FDT	Ramosetron	████████████████████	████████████████████	████████████████████
	CSDS	Prednisolone	████████████████████	████████████████████	████████████████████
	SENS	SYP-1758	████████████████████	████████████████████	████████████████████
		SYP-1765	████████████████████	████████████████████	████████████████████
SYP-1914		████████████████████	████████████████████	████████████████████	
Metabolic Anticancer	SYO-2001	████████████████████	████████████████████	████████████████████	
USA	Monoclonal antibody	SYB-010	████████████████████	████████████████████	
		SYB-020	████████████████████	████████████████████	

CEO
Taeung Eom

Location
6th Floor, 295 Pangyo-ro,
Bundang-gu, Seongnam-si,
Gyeonggi-do, South Korea

- Specialty
1. Drug delivery system of anti-cancer drugs based on small molecules, virus and nucleic acid
 2. New biologic anticancer drugs and Rare disease drugs
 3. Cytotoxic anticancer drugs

Tel / Fax / E-mail
T. 82-2-2157-9111
F. 82-2-2157-9062

CONTACT US

Technology Transfer / Licensing

Hojin Chung
Business Development/
Senior Manager
T. +82-2-2157-9872
E. hojin.chung@samyang.com

Overseas export

Hyemin Kang
Overseas Business Team/
Assistant Manager
T. +82-2-2157-9862
E. hyemin.kang@samyang.com

Overseas Office

Seyoon Kim
Business Development/
Senior Manager
T. +1-617-812-6969
E. bd@samyang.com

Etc.

Kim Jin Woo
Business Administration
T. +82-2-2157-9808
E. jinwoo.kim11@samyang.com



sanofi-avenetis Korea

CEO
Kyung-eun (Kay) Bae

Location
235, Banpo-daero, Seocho-gu,
Seoul Republic of Korea

Specialty
CV, Diabetes, Oncology, im-
munology, rare disease and
consumer health

Tel / Fax / E-mail
T. 82-2-2136-9000
F. 82-2-2136-9099
E. infor@sanofi.com

Sanofi-Aventis Korea is a Korean legal entity of the global biopharmaceutical company, Sanofi based in France. We provides innovative healthcare solutions fulfilling patients' needs in immunology, oncology, rare disease, Cardio-vascular and consumer healthcare. With the first foot print in Korea with collaborations with Handok as Hoechst in 1957, Sanofi-Aventis Korea has contributed to Korea healthcare by providing innovative solutions and driving open-innovation from research to development stage leveraging R&D organizations in Korea.

Main Products

Therapeutic area	Product	Generic Name
Diabetes	Toujeo	Insulin Glargine
	Lantus	Insulin Glargine
Thrombosis and cardiovascular disease	Plavix	Clopidogrel Bisulfate
	Aprovel	Irbesartan
	Praluent	Alirocumab
	Rovelito*	Irbesartan-Atorvastatin
Kidney disease	Renvela	Sevelamer Carbonate
Cancer	Eloxatin	Oxaliplatin
	Taxotere	Docetaxel Trihydrate
Immunology disease	Dupixent	Dupilumab
Rare disease	Fabrazyme	Agalsidase Beta (recombinant human alfa galactosidase A)
	Alprolix	Eftrenonacog alfa (coagulation factor IX-Fc fusion protein)
	Eloctate	Efmorotocog alfa (Antihemophilic factor, Fc Fusion Protein)
Intestinal diseases	Dulcolax	Bisacodyl

* Rovelito is co-developed and co-promoted with Hanmi Pharmaceutical.
For more product information, refer to the corporate website(www.sanofi.co.kr).

R&D Pipeline

TA	Compound	Indication	Development phase					
			Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Launch
Immunology	Dupilumab	Asthma						
Immunology	Dupilumab	COPD						
Immunology	Dupilumab	Prurigo Nodularis						
Immunology	SAR440340 (anti-IL33 mAb)	Asthma						
Immunology	Sarilumab	Rheumatoid Arthritis						
Rare disease	GZ402666 (NeoGAA)	Late onset Pompe Disease						
Rare disease	Venglustat	Autosomal Dominant Polycystic Kidney Disease						
Multiple Sclerosis	SAR442168 (BTKi)	Relapsed Multiple Sclerosis						
Rare Blood disease	Fitusiran	Hemophilia A, B						
Oncology	SAR408701 (anti-CEACAM5 mAb ADC)	NSCLC						
Oncology	Isatuximab	Multiple Myeloma						
Oncology	Isatuximab	Smoldering Multiple Myeloma						
Oncology	Isatuximab	Lymphoma						
Oncology	Isatuximab	Pediatric ALL/AML						
Oncology	SAR439859 (SERD)	Breast Cancer						
Oncology	SAR441000 (cytokine mRNA)	Advanced Solid Tumor						
Oncology	SAR439459 (TFGb)	Advanced Solid Tumor						
Oncology	epfeglenatide	Diabetes Mellitus						
Oncology	sotagliflozin	Diabetes Mellitus						

CONTACT US

Technology Transfer / Licensing

SangGyun Kim
Research / Head
T. +82-10-7410-8307
E. sanggyun.kim@sanofi.com

Etc.

Sunyoung Yi
Public Affairs / Head
T. +82-10-9097-2304
E. sunyoung.yi@sanofi.com



신웅제약(영문)

SHIN POONG PHARM. CO., LTD.

shinpoong.co.kr/en/main/main.php

Shin Poong Pharm is a R&D oriented pharmaceutical company with global presence in over 50 countries. (Main: CV, bone disease and anti-infectives)

We specialize in manufacturing remedy drugs ranging from active ingredients to finished products based on our state-of-the-art manufacturing facilities and QC system. Under the management philosophy of 'For the Health of the People', we are committed to realizing it with top-notch competitiveness through rigorous efforts in R&D and steady reliability from customers.

Main Products



Name	Indication	Phase	Classification
Pyramax [®] Tablet	Malaria	On Market	NCE
Pyramax [®] Granule	Malaria (Pediatric formulation)	On Market	NCE
CandeAmlo [®] Tablet	Hypertension	On Market	IMD/FDC
EzeRosu [®] Tablet	Hyperlipidemia	On Market	IMD/FDC
Hyal Forte [®] Injection	Osteoarthritis	On Market	Generic

※ NCE (New Chemical Entity), NME (New Molecular Entity), IMD (Incrementally Modified Drug)

R&D Pipeline

Category	Products	Indication	Stage
NCE	Otaplimastat (SP-8203)	Acute Ischemic Stroke	Phase 2b (Korea) On-going
	SP-8008	Anti-platelet	Phase 1 (Europe) On-going
	SP-8356	Cerebro-cardiovascular diseases	Preclinical (Europe) Completed
	SP5M001	Osteoarthritis (Long-lasting viscosupplement)	Phase 1/2 (Korea) On-going
	SP-8416	Heart failure	Lead optimization On-going

※ NCE (New Chemical Entity)

CEO
Jei Man Ryu

Location
161, Yeoksam-ro, Gangnam-gu, Seoul, 06246, Republic of Korea

Specialty
1. Composition of raw materials and production lines for antibiotics
2. New drugs and first generic drugs
3. Raw Materials

Tel / Fax / E-mail
T. 82-2-2189-3400
F. 82-2-553-2578
E. sprade@shinpoong.co.kr

CONTACT US

Technology Transfer / Licensing

Yong Jin Kim
BD / Senior Manager
T. +82-2-2189-3483
E. yjkim@shinpoong.co.kr

Overseas export

J S, Hong
Global Business / AM
T. +82-2-2189-3509
E. jangsun@shinpoong.co.kr

Overseas Office

lion kim
Global Business / PM
T. +82-2-2189-3506
E. khs@shinpoong.co.kr

Etc.

Simon Yu
Global Business / PM
T. +82-2-2189-3490
E. swyuni@shinpoong.co.kr



ST PHARM

cGMP compliant ST Pharm is providing top manufacturing services to satisfy our customers' high expectations to use our products in pharmaceutical industry. As a member of Dong-A Socio Holdings, ST Pharm is proactively investing our manufacturing equipments to provide cutting edge services which are comprehensive and matching to the fast phased global market. ST Pharm will continually challenge ourselves to prosper as not only a leading pharmaceutical company but also a global chemical company.

Main Products

Category	Products	Customer	Indication/Stage
New Drug APIs	HCV drug	Originator (Global)	HCV/Marketed
	Diabetes drug	Originator (Global)	Diabetes/Marketed
	Antibiotics drug	Originator (Global)	Antibiotics/Marketed
	Gastric Cancer	Originator (Global)	Gastric Cancer / Phase 3
	Mitochondrial DNA Depletion Syndrome	Originator (Global)	MDDs/Phase 3
Pharmaceutical Intermediates	Chiral epoxide	Originator (Global)	HIV/Marketed
	Chloro-(L)-sugar	Originator (Global)	HBV/Marketed
	Nucleoside monomers	US/EP/JP	Various RNA therapeutics/Clinical
APIs	Atorvastatin	Domestic/JP	Hyperlipidemia/Marketed
	Clopidogrel	Domestic	Anticoagulant/Marketed
	d-Cycloserine	Domestic/JP/WHO/ROW	Tuberculosis/Marketed
	Terizidone	S.Africa/Germany/CIS	Tuberculosis/Marketed
	Gadobutrol	Domestic/EU/CIS	MRI contract/Marketed

R&D Pipeline

Category	Project (Indications)	Stage (on going)
New Drug	STP1002 (cancer)	Phase I
	STP0404 (HIV ALLINI)	Phase I
	STP3725 (Anticoagulants)	Preclinical
	NASH	Discovery
	IBD	Discovery
	Influenza	Discovery

CEO
Kyungjin Kim

Location
231, Hyeomnyeok-ro, Siheung-si, Gyeonggi-do, 15086 Korea

Specialty
Oligo APIs and New Drug Development, CMO(New Drug APIs & Intermediates), Generic APIs

Tel / Fax / E-mail
T. 82-2-527-6351
F. 82-2-561-6006
E. ywshin@stpharm.co.kr

CONTACT US

Technology Transfer / Licensing

Seohyun Ahn
New Drug Development
T. +82-2-527-6331
E. seohyun.ahn@stpharm.co.kr

Domestic Sales

Dong-Soo Lee
Generic APIs
T. +82-2-527-6364
E. dslee01@stpharm.co.kr

Overseas Sales

Kris S. Choi
Marketing & Business Development /Bio Division
T. +82-2-527-6329
E. choicsw@stpharm.co.kr



For Happiness of Humanity and Respect for Life

Taejoon Pharmaceutical Co., Ltd.

www.taejoon.co.kr/en

CEO
Tae Young Lee

Location
8 Daesagwan-ro 31 gil,
Yongsan-gu, Seoul, Republic
of Korea

Specialty
1. Ophthalmic IMD
2. Contrast media IMD
3. GI IMD

Tel / Fax / E-mail
T. 82-2-798-6601
F. 82-2-798-6608

Established in 1978, Taejoon is one of the leading specialty pharmaceutical companies in ophthalmology, radiology, and GI. With a global presence in the US, Europe, Asia and Africa, Taejoon has been building up company's future growth based on the business strategy by focusing its corporate resources; specialization, global marketing, and R&D innovation. In particular, Taejoon has acquired US and European GMP certifications to secure global competitiveness and maintains state-of-the-art manufacturing facilities.

Main Products

Product (Ingredient/Formulation)	Use	Exporting Countries	Remarks
Cyporin N Eye drop 0.05% (Cyclosporin)	Dry eye		Launched
Xalost-S Ophthalmic Solution (Latanoprost)	Glaucoma		Launched
Xalostplus Ophthalmic Solution (Latanoprost, Timolol maleate)	Glaucoma	EU, Hong Kong	Launched
Xalost Ophthalmic Solution (Latanoprost)	Glaucoma	EU, China, Nigeria	Launched
Gadobirx Pre-filled Syringe Injection (Gadobutrol)	Contrast enhancement of cranial and spinal MRI		Launched
Iobrix INJ 350 (Iohexol)	Contrast enhancement	Thailand, Philippines	Launched
CleanViewAL Powder (Polyethylene glycol3350)	Bowel cleansing		Launched

R&D Pipeline

Category	Project	Indication	Development process					
			Discovery	Preclinical	Phase I	Phase II	Phase III	Launch
IMD	Undecided	Eye disease	█	█				
IMD	Undecided	Eye disease	█	█	█	█	█	
IMD	Undecided	Eye disease	█	█				
IMD	Undecided	Gastrointestinal disease	█					
IMD	Undecided	Gastrointestinal disease	█	█				

CONTACT US

Technology Transfer / Licensing

Jun Hee Lee
Business Development / Director
T. +82-2-799-0072
E. jhlee2@taejoon.co.kr

Overseas export

Ga Ram Choi
Business Development / Assistant Manager
T. +82-2-799-0164
E. grchoi@taejoon.co.kr



TEGO SCIENCE

A World Leader in Cell Therapy & Advanced Regenerative Medicine

Tego Science is a Seoul-based biopharmaceutical company specializing in regenerative skin cell therapy for wound healing. Tego's chief strengths have been leading-edge technologies in cell culture, skin-graft manufacturing and cryopreservation. It is now evolving into wider regenerative medicine areas involving musculo-skeletal, ophthalmological and dermatological targets, with plans for overseas expansion. Tego Science has been listed in KOSDAQ since 2014.

Main Products



CEO
Saewha Jeon

Location
93, Magokjungang 8-ro,
Gangseo-Gu, Seoul 07794,
Korea

- Specialty
1. Dermatological cell therapy,
 2. Musculo-skeletal cell therapy
 3. Ophthalmological cell therapy

Tel / Fax / E-mail
T. 82-2-818-2900
F. 82-2-2107-3173
E. swbaek@tegoscience.com

Product(Ingredient/Formulation)	Use	Exporting Countries(E)	Remark
Holoderm® (Autologous Keratinocytes)	3rd degree burn		Launched
Kaloderm® (Allogenic Keratinocytes)	Deep 2rd degree burn, Diabetic Foot Ulcer	Mongolia, Indonesia	Launched
Rosmir® (Autologous Fibroblasts)	Wrinkles	Vietnam	Launched
Neoderm® (3D Human Skin)	Replacing animal testing	Japan	Launched

R&D Pipeline

Project / Cell & Protein therapy	Indications	Discovery	Pre-Clinical	Clinical Trial			NDA
				I	II	III	
TPX-114 / Dermal fibroblasts (auto)	Full-thickness rotator-cuff tear	→					
TPX-115 / Dermal fibroblasts (allo)	Partial-thickness rotator-cuff tear	→					
TPX-113 / Keratinocytes (auto/allo)	Oral mucosal defects	→					
TPX-107 / Mucosal keratinocytes (auto)	Corneal defects	Investigator Initiated Trial					
TPX-109/ Chemokine	Cartilage defects	→					

* Arrows indicate current progress with MFDS.

CONTACT US

Technology Transfer / Licensing
Overseas export
Overseas Office
Etc.

Seungwun Baek
Business Development / Team Manager
T. +82-2-818-2900
E. swbaek@tegoscience.com



Great Yuhan, Global Yuhan



eng.yuhan.co.kr

Yuhan Corporation

CEO
Jung Hee Lee

Location
74, Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, Korea

- Specialty
1. Anticancer Chemical New drug
 2. Circulatory System Incrementally Modified Drugs

Tel / Fax / E-mail
T. 82-2-828-0181
F. 82-2-828-0300

Yuhan Corporation has increased the R&D investments since 2015. We licensed out KRW 2.5 trillion worth of technology in 2018, 2019 on licensing and the joint R&D for a new therapeutic candidate treating nonalcoholic steatohepatitis (NASH). As our pipelines continue to expand, today they stand at 27 breakthrough therapies and five IMDs. In pursuit of breakthrough therapies, there are 17 ongoing oncology programs, including immunotherapies and next-generation targeted drugs to fight cancer, such as Lazertinib.

Main Products

Products	Ingredients	Indications	Exporting Countries
Pregabalin SR Tablet	Pregabalin	Neuropathic pain	
Duowell Tablet	Telmisartan, Rosuvastatin	Treatment for hypertension and hyperlipidemia	Uzbekistan
Rosuampine Tablet	Amlodipine, Rosuvastatin	Treatment for hypertension and hyperlipidemia	
Rosumet SR Tablet	Metformin SR, Rosuvastatin	Antidiabetic	
Newfactan	Bovine Lung Surfactant	Treatment for respiratory distress syndrome of newborns	Vietnam, Mongolia, Bolivia
Yucla Tablet	Amoxicillin, Clavulanate Potassium	Antibiotics	
Almagate Suspension	Almagate	Antiacidic functions	
Antiplamine S Lotion	Methyl Salicylate, L-menthol	Anti-inflammatory agent	Vietnam, Malaysia
Willogel Double Action Suspension	Sodium alginate, Calcium carbonate, Sodium bicarbonate	Alleviation of heartburn and indigestion	
Nazacare Nasal Spray Solution	Mometasone Furoate	Nasal symptoms of allergic rhinitis, Nasal polyps, Acute rhinosinusitis	

CONTACT US

Technology Transfer / Licensing

Josephine Cho
Licensing team / Team manager
T. +82-2-828-0093
E. josephine@yuhan.co.kr

Overseas export

Tommy Lee
Overseas Business / Assistant manager
T. +82-2-828-0049
E. tommy@yuhan.co.kr

R&D Pipeline

Category	Name	Indication	Discovery	Preclinical study	Phase 1	Phase 2	Phase 3
NCE	Lazertinib	NSCLC				██████████	
	YH12852	POI				██████████	
	YHC1102	NASH	██████████				
	YHC1108	NASH	██████████				
	YHC1116	Gaucher	██████████				
	YHC1104	NSCLC	██████████				
Biologics	YH14618	Degenerative Disk				██████████	
	YH25724	NASH		██████████			
	YH24931	Immuno-oncology	██████████				
	YHC2121	Immuno-oncology	██████████				
	YHC2120	Immuno-oncology	██████████				
	YHC2110	Obesity	██████████				



Yungjin Pharm. Co., Ltd.

Since its establishment in 1952, YUNGJIN PHARM. CO., LTD. has been a pioneer in the Korean domestic pharmaceutical industry for national economic development and improving public health with the lofty mission of saving humanity from disease and suffering through our medicines. As an affiliate of KT&G Group, YUNGJIN plays a pivotal role in the bio/pharmaceutical business within the group with outstanding drug production and R&D know-how, and has grown into a global pharmaceutical company by developing new products and expanding exports.

Main Products

Product	Ingredient	Exporting Countries	Remarks
CEROCAPENE	Cefcapene Pivoxil	Worldwide	API, tab., fine gran.
CEFDITOREN	Cefditoren Pivoxil	Worldwide	API, tab., fine gran.
CEFMETAZOLE	Cefmetazole Sodium	Worldwide	API, inj.
CEFOTIAM	Cefotiam HCl/HCl+Na2CO3	Worldwide	API
CEFTRIAZONE	Ceftriaxone Sodium	Worldwide	inj.
CEFTAZIDIME	Ceftazidime Hydrate	Asia	inj.
CEFOXETIL	Cefpodoxime Proxetil	Asia	API, tab., DS
CEROFAZIL	Cefprozil Hydrate	Asia	tab., DS
CEFDINIR	Cefdinir Hydrate	Asia	API, tab., fine gran.
LOXOPROFEN	Loxoprofen Sodium	Worldwide	API
CANDESARTAN	Candesartan Cilexetil	Asia	API, tab.
FEBUXOSTAT	Febuxostat	Worldwide	API
LINEZOLIN	Linezolid	Worldwide	tab.
YUNGPENEM	Imipenem, Cilastatin	Worldwide	inj.
BAROSCON DOUBLE ACTION	Sodium alginate, calcium carbonate, sodium bicarbonate	Worldwide	susp.
Pediatric Complete Multivitamin	Multivitamins	Worldwide	syr.

R&D Pipeline

Project Name	Therapeutic Area	Indication	Development Status				
			Research	Nonclinical	Phase I	Phase II	Phase III
YPL-001	Respiratory	COPD (Asthma)	████████████████████				
YRA-1909	Immunology	Rheumatoid Arthritis	████████████████████				
KL1333	Metabolic Disorder	Mitochondrial Disease	████████████████				
YPN-005	Oncology	Cancer	██████████				
YPN-006	Oncology	Immuno-oncology	██				
YPI-005	Other Blood Related	Spinal Stenosis	███				
YPI-008	Cardiovascular	Hypertension Dyslipidemia	██████				
YPI-009	Gastrointestinal	Gastroesophageal Reflux Disease	███				
YPI-010	Respiratory	Idiopathic Pulmonary Fibrosis	████				

CEO
Chae Joon Lee

Location
13, Olympic-ro 35da-gil, Songpa-gu, Seoul, 05510, Korea

- Specialty
1. NCE(Targeted cancer therapy, Cancer immunotherapy, Rare disease)
 2. IMD & Generic (Cephalosporins, Antipyretic-analgesics & Anti-inflammatory, CNS, Rare disease)
 3. API(Cephalosporins, Anti-hypertension, Anti-inflammatory, Analgesic)

Tel / Fax / E-mail
T. 82-2-2041-8200
F. 82-2-2041-8201

CONTACT US


Technology Transfer / Licensing

Yongnam Lee
BD&L Division / Senior Manager
T. +82-2-2041-8221
E. nami0209@yungjin.co.kr

Sunyoung Jung
BD&Licensing division / Manager
T. +82-2-2041-8227
E. syjung@yungjin.co.kr

Overseas export

Yunhee Kim
Global Business Department / Assistant Manager
T. +82-2-2041-8246
E. yunhee.kim@yungjin.co.kr





Supplement

1. Products Expected to Export
2. Technology Transfer
3. Certifications from Health Authorities

1. Products Expected to Export

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
Alteogen, Inc.	ALT-B4	Hyaluronidase	IVF	Media	Global	
	ALT-L9	Aflibercept	wetAMD	Injection		
BCWORLD PHARM. CO., LTD.	Mepem inj. 1g	Meropenem	Antibiotics	Prescription Medicine	Global	
	Mepem inj.500mg	Meropenem	Antibiotics	Prescription Medicine	Global	
	Sinraci inj. 500mg	Imipenem/Cilastatin sodium	Antibiotics	Prescription Medicine	Global	
	Merogel	Metronidazole	Antibiotics	Prescription Medicine	Global	
	Multipotent inj.	Zn, Cu, Se, Cr, Mn, F, Fe, I, Mo	Well-being product	Prescription Medicine	Global	
Boryung Pharmaceutical co.,Ltd.	Kanarb®	Fimasartan	Hypertension	Prescription Medicine	CHINA, BRAZIL, PERU, ECUADOR, MENA, CIS, EU	
	Kanarb Plus®	Fimasartan with HCTZ	Hypertension	Prescription Medicine		
	Dukarb®	Fimasartan with Amlodipine	Hypertension	Prescription Medicine		
	Tuvero®	Fimasartan with Rosuvastatin	Hypertension/Dyslipidemia	Prescription Medicine		
	Alimxid Inj.	Pemetrexed	Antineoplastic	Prescription Medicine	MENA, LATAM, ASIA, CIS	
	Velkin Inj.	Bortezomib	Antineoplastic	Prescription Medicine	MENA, LATAM, ASIA, CIS	
	Gelfos®	Colloidal Aluminum Phospate	Gastric Hyperacidity Heartburn	Non-Prescription Medicine	HONGKONG THAILAND INDONESIA	
	Besto®	Lafutidine	Gastric ulcer	Prescription Medicine	MENA LATAM ASIA	
Bukwang Pharmaceutical Co., Ltd.	Dexid® tab.	R-thioctic acid tromethamine	Diabetic polyneuropathy	Prescription Medicine	Global	Agreement reached in Southeast Asia
CKD Pharmaceutical Corp.	Duvie Tab.	Lobeglitazone sulfate	Type 2 diabetes	NCE(New Chemical Entity)	ASEAN	Korea's 20th new drug
	Nesbell PFS Inj.	Darbepoetin- α	1. Anemia associated with chronic renal failure 2. Anemia by cancer chemotherapy	Biologic drug /2 nd generation EPO Biosimilar	ASEAN	The world's first NESP biosimilar and the first bio medicine of CKD
	Pemecine liquid Inj.	Pemetrexed disodium 2.5 hydrate	1. Non-small cell lung cancer 2. Malignant pleural mesothelioma	Chemical generic drug	US, Europe	
	Esoduo Tab.	Omeprazole+Sodium bicarbonate	Gastroesophageal reflux disease (GERD)	IMD (Incrementally Modified Drug)	US, Europe	The world's first and only IR-Esomeprazole as an IMD
Corestem Inc.	Neuronata-R®	Autologous bone marrow derived mesenchymal stem cell (lenzumesrocel)	amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease)	Stem cell Therapy Product	Global	MFDS Approval (2014.07), Release (2015.01)
Crystal-Genomics, Inc	Acelex 2mg	Polmacoxib	Osteoarthritis	Small molecule	Global	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
DAEHWA PHARMACEUTICAL CO., LTD.	Liporzel solution	Paclitaxel	Advanced and metastatic or local recurrent gastric cancer	IMD	Global	
	Rivamensa patch	Rivastigmine	Mild to moderately severe dementia of the Alzheimer type dementia associated with Parkinson's disease	Generic	Global	
	Demacot cream	Gentamycin Sulfate Betamethasone Dipropionate Clotrimazole	Allergic and inflammatory dermal infections;	Generic	Global	
	Pure gel	Erythromycin Tretinoin	Treatment of acne	Generic	Global	
	Kebanon plaster	Ketoprofen	Muscular pain	Generic	Global	
	Top-roll soft capsule	Ginseng powder and others	Treatment of acne	Generic	Global	
Daewon Pharmaceutical Co., Ltd.	Pelubi CR	pelubiprofen	Osteoarthritis, Rheumatoid, Back pain,	Originator	Global	
	Freefol MCT	Propofol	Anesthesia	Generic	Global	
	Renamezin	oral adsorptive charcoal	chronic renal failure	Generic	Global	
	TG-fenon	Choline fenofibrate	Hypertriglyceridemia	IMD	Global	
Daewoong Pharmaceutical	TBD	Fexuprazan	Anti-Peptic Ulcer	Originator	Brazil, Mexico	
	Nabota	Botulinum toxin	Glabella lines	Originator	US, Canada, MENA, LATAM, EU, ASIA, Australia	
	TBD	Enavogliflozin	Type 2 diabetes	Originator		
	Olostar	Olmesartan/ Rosuvastatin	Concomitant hypertension and dyslipidemia	Originator	Mexico, Bolivia, Ecuador, Central America, Malaysia, USA, Canada, Australia, Jordan, Iraq	
	Easyef	Recombinant human Epidermal Growth Factor	Diabetic foot ulcer	Originator	Ecuador Bolivia, CIS, SriLanka, Jordan, Iraq	
	Ursa	Ursodeoxycholic acid	Cholestasis (including PBC, PSC), viral hepatitis C, gallstone	Originator	Bolivia CIS Malaysia Ecuador, Singapore, Brunei, Philippines, China, Vietnam, Cambodia, Jordan, Iraq	
	Eposis	Recombinant human Erythropoietin α	Anemia in end stage renal disease (ESRD)	Biosimilar	Indonesia, SriLanka, Thailand, Philippines, Iraq	
	Luphere	Leuprorelin Acetate	Prostate cancer, endometriosis, uterine fibroid, postmenopausal breast cancer, central precocious puberty	Generic	Japan, Malaysia, Russia, Philippines	
GC Pharma	I.V.-Globulin SN inj.	Human Intravenous Immunoglobulin	A-/Hypogammaglobulinemia Combined therapy with antibiotics for severe bacterial or viral infections Idiopathic thrombocytopenic purpura Guillain-Barres syndrome Kawasakis syndrome	Plasma Derivatives	Asia, Middle-East, Central & South America	
	Albumin inj.-GCC	Human Albumin Solution	For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)	Plasma Derivatives	Asia, Middle-East, Central & South America	
	Green-VIII inj.	Human Blood Coagulation Factor VIII	For the treatment of hemophilia A with supplies of blood coagulation factor VIII	Plasma Derivatives	Asia, Middle-East, Central & South America	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
GC Pharma	GreenGene F inj.	Recombinant Coagulation Factor VIII	For the prevention and control of bleeding episodes and preoperative management in hemophilia A	Recombinant Product	Asia, Middle-East, Central & South America	
	Hepabig inj.	Human Hepatitis B Immunoglobulin	For prophylaxis of hepatitis B after exposure to HBsAg For prophylaxis of hepatitis B in neonates	Plasma Derivatives	Asia, Middle-East, Central & South America	
	I.V. Hepabig inj.	Human Hepatitis B Immunoglobulin	For prevention of recurrence of hepatitis B in patients with liver transplants	Plasma Derivatives	Asia, Middle-East, Central & South America	
	Sero-Tet inj.	Human Tetanus Immunoglobulin	For the prophylaxis of tetanus and the reduction of tetanus symptoms	Plasma Derivatives	Asia, Middle-East, Central & South America	
	GCFLU PFS inj.	Split Virion, Trivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Vaccines	Asia, Middle-East, Central & South America	
	GCFLU Quadrivalent PFS inj.	Split Virion, Quadrivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Vaccines	Asia, Middle-East, Central & South America	
	Varicella vaccine-GCC inj.	Live Attenuated Varicella Vaccine	For the prophylaxis against varicella	Vaccines	Asia, Middle-East, Central & South America	
	Hunterase	Idursulfase beta	For treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)	Recombinant Product	Asia, Middle-East, Central & South America	
	Neulapeg PFS Inj.	PEG-GCSF	For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma	Recombinant Product	Asia, Middle-East, Central & South America	
Handok Inc.	KETOTOP Plaster	Ketoprofen	Degenerative arthritis (Osteoarthritis), Periarthritis, humeral epicondylitis (tennis elbow etc.), Peritendinitis, tendinitis, tendovaginitis, myalgia, post-traumatic swelling/pain	Drug	Global	
	READY Q Drink	Curcumin	Use for Hangover remedies	Food & Beverage	Global	
	READY Q Chew	Curcumin	Use for Hangover remedies	Food & Beverage	Global	
HANLIM PHARM. CO., LTD.	Nasaflex Nasal Spray	Mometasone furoate, Azelastine HCl	Perennial allergic rhinitis	Allergy & ENT	Global	
	T-Sporin Eye Drops	Cyclosporin	Increase tear production	Ophthalmic	Global	
	Hyaluron Eye Drops (Single dose)	Sodium Hyaluronate	Endogenous disease, dry eye syndrome	Ophthalmic	Global	
	Risenex Plus Tab.	Sodium Risedronate, Cholecalciferol	Osteoporosis	Endocrine	Global	
	Heparin Sodium Inj.	Heparin Sodium	Anticoagulant	Anticoagulant	Global	
	Hanlim Vasopressin Inj.	Vasopressin	Pituitary hormone agent	Endocrine	Global	
Hanmi Pharm. Co., Ltd	Amosratan	Amlodipine + Losartan	Hypertension	CV	CIS	
	Amosartan Q	Amlodipine + Losartan + Rosuvastatin	Hypertension & Hyperlipidemia	CV	LATAM	
	Amosartan Plus	Amlodipine + Losartan + Chlorthalidone	Hypertension	CV	LATAM	
	Rovelito	Atorvastatin + Irbesartan	Hypertension & Hyperlipidemia	CV	LATAM	
	Rosuzet	Rosuvastatin + Ezetimibe	Primary Hypercholesterolemia & Hyperlipidemia	CV	CIS, LATAM SEA	
	Gugutams	Tamsulosin + Tadalafil	ED, BPH	Urology	CIS LATAM	
	Monterizine	Montelukast+ Levocetirizine	Asthma Rhinitis	Respiratory	LATAM SEA	
	Hyalrheuma	Hyaluronic acid	Osteoarthritis	OA	EU MENA	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
HK inno.N Corporation	K-CAB Tab.	Tegoprazan	Gastroesophageal reflux disease (GERD)	Antiulcer	Global	
	Exone-R Tab.	Amlodipine + Valsartan + Rosuvastatin	Hypertension with dyslipidemia	Fixed Dose Combination		
	Exone Tab.	Valsartan + Amlodipiney	Hypertension			
	Atomet XR Tab.	Atorvastatin/Metformin	Type2 Diabetes/Hyperlipidemia			
	Machkhan Tab.	Candesartan/Amlodipine	Hypertension			
	Rovazet Tab.	Ezetimibe + Rosuvastatin	Hyperlipidemia Primary hypercholesterinemia			
	Cinezolid Tab&Inj.	Linezolid	Infection			Antibiotics
	Moveloxin Inj.	Moxifloxacin	Infection			
	Citopcin Inj.	Ciprofloxacin	Infection			
	Levotopcin Inj.	Levofloxacin	Infection			
	Tapocin Inj.	Teicoplanin	Infection			
	Vancorin Inj.	Vancomycin	Infection			
	Epokine Inj.	Erythropoietin	Anemia	Biologicals		
	Pemta RTU Inj.	Pemetrexed	Cancer	Oncology		
	Calmtop Inj.	Irinotecan	Cancer			
	OmapOne Peripheral Inj.	Lipid, Amino acid, Glucose	Total Parenteral Nutrition (TPN)	IV Solution (3-chamber bag)		
Enteone Tab.	Entecavir	Hepatitis B infection	Antiviral			
HUONS CO., LTD.	Norepirin inj.	Norepinephrine Bitartrate 8mg/4mL	Cardiac surgery post-op low cardiac output, Acute hypotension, Shock, Cardica arrest	Drug	Vietnam, Thailand	
	Clacier Eye drop	Cyclosporine 0.2mg/0.4mL	Dry eye, anti-inflammation	Drug	China, Iraq, Saudi Arabia, Jordan, Taiwan, Indonesia, Vietnam, Malaysia	
	Kynex 2 Eye drop	HA 0.63mg/0.35ml	Dry eye	Drug	Thailand, Vietnam	
	Huons Lidocaine HCl 2% with Epinephrine inj. 1:100,000/1:80,000	Lidocaine HCl 36mg/1.8mL, Epinephrine Bitartrate 0.0324mg /LidocaineHCl 36mg/1.8mL, Epinephrine Bitartrate 0.04104mg	Dental local anesthesia	Drug	China, Philippines, Taiwan, Indonesia, Kazakhstan, Ukraine, Paraguay, Brazil, Mexico	
	Huons Articaine HCl 4% with Epinephrine inj. 1:100,000	Articaine HCl 40mg/mL, Epinephrine Bitartrate 0.018mg	Use in topical, infiltration and conduction anesthesia in dentistry	Drug	Kazakhstan, Tajikistan, kyrgyzstan, Ukraine, Mongolia, Taiwan, Indonesia, Pakistan, Malaysia	
	Lidocaine HCl 1%	Lidocaine HCl 10mg	Nerve block and infiltration	Drug	Taiwan	
	Ginkobal inj.	Ginkgo Biloba Leaf Extract 17.5mg/5mL	Blood circulation promoter	Drug	China	
	Bupivacaine Hydrochloride in Dextrose Injection, USP	0.75% Bupivacaine 0.85% Dextrose Inj. (2ml Ampoule)	Spinal cord aensthesia	Drug	USA	
	Lidocaine HCl in Epinephrine Injection, USP	1.5% Lidocaine Epinephrine Inj. (5ml, ampoule)	Local anesthesia	Drug	USA	
	Lidocaine HCl Injection, USP	1% Lidocaine inj. (5ml Vial)	Local anesthesia	Drug	USA	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
Hyundai Pharm Co.,Ltd	Levotuss Tab. /Syrup	Levodropropizine	Cough : acute and chronic bronchitis	First MA (Marketing authorization)	Global	
	Uremin Tab	Desmopressin acetate	Nocturnal enuresis	Generic	Global	
	Tamirin SR Tab	Galantamine HBr	Alzheimer's disease	First MA (Marketing authorization)	Global	
	Mirap ER Tab.	Pramipexole HCl	Parkinson's disease	Generic	Global	
	Minoxyl Gel / Sol.	Minoxidil	Alopecia	Generic	Global	
ILDONG Pharmaceutical Co., Ltd.	Besivo Tab.	Besifovir	Hepatitis B virus (HBV) infection	Antiviral	SEA, CIS, Latin America, MENA	
	Algik Inj.	Pemetrexed	Pleural mesothelioma, NSCLC (Non-small cell lung cancer)	Anticancer	South East Asia Latin America, CIS	
	Vicure Tab.	Entecavir	Hepatitis B virus (HBV) infection	Antiviral	SEA, Latin America, CIS	
	TBD	Rivaroxaban	Prevent blood clots	Anticoagulant	TBD	
	Droptop Tab.	Rosuvastatin+Ezetimibe	Hypercholesterolemia	HMG-CoA reductase inhibitor	SEA	
	Memanto Tab.	Memantine	Moderate-to-severe Alzheimer's disease	NMDA Receptor Blocker	SEA	
	Reyyow (tentatively named)	Iasmiditan	Acute Migraine	Anti-migraine agent	Southeast Asia	
ISU Abxis	Abcertin®	Imiglucerase	Gaucher Disease	Injection	Global (excluding Korea, Iran, Mexico)	
	Fabagal®	Agalsidase beta	Fabry Disease	Injection	Global (excluding Korea)	
	Clotinab®	Abciximab	Anti-thrombotic	Injection	Global (excluding Korea, Turkey)	
JW Pharmaceutical	Combiflex Lipid	Refined soybean oil, Glucose, Amino Acid, Electrolytes	Supply of all Nutrition	I.V Solution	Global	
	Lipision	Refined soybean oil	Lipid based IV Solution	I.V Solution	Global	
	Freamine	15 amino acids	Amino Acid IV Solution	I.V Solution	Global	
	Nephramine	8 amino acids & 4 electrolytes	Amino Acid IV Solution	I.V Solution	Global	
	Prepenem	Imipenem, Cilastatin	Carbapenem Antibiotics	Antibiotics	Global	
	Pospenem	Meropenem	Carbapenem Antibiotics	Antibiotics	Global	
	Ertapenem	Ertapenem	Carbapenem Antibiotics	Antibiotics	Global	
	Doripenem	Doripenem Anhydrous	Carbapenem Antibiotics	Antibiotics	Global	
	Levofloxacin	Levofloxacin	Quinolone Antibacterial Agent	Antibacterial	Global	
	Heparin	Heparin	thrombosis	Anticoagulant	Global	
	J-Dart tab.	Dutasteride	BPH, Alopecia	Urological	Global	
	Levetiram Premix	Levetiracetam	Epilepsy	Premix	Global	
	Acetamin Premix	Acetaminophen	Pain	Premix	Global	
	Levetiram Premix	Levetiracetam	Epilepsy	Premix	Global	
	Acetamin Premix	Acetaminophen	Pain	Premix	Global	
Kolmar Korea Co., Ltd.	Entekim Tab	Entecavir 0.5mg	Treatment of chronic hepatitis B virus	Oral solid (Tablet)	Hong kong, Macao	
	Bacterocin Oint	Mupirocin 20mg/g	Treatment of secondarily infected traumatic lesions	Topical Ointment	Hong kong	
	Calcibeta Oint	Betamethasone 0.643mg, Calcipotriol 52.2µg	Treatment of psoriasis	Topical Ointment	Hongkong	
	Munals double action	Sodium Alginate 5g, Calcium Carbonate 3.25g, Sodium Bicarbonate 2.13g	Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the esophagus such as acid regurgitation, heartburn and indigestion	Oral Solution	-	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
Korea United Pharm. Inc.	Clanza®CR Tab.	Aceclofenac 200mg	Chronic pain management	Prescription Medicine	Global	Controlled Release Formulation
	Cilostan®CR Tab.	Cilostazol 200mg	Ischemic symptoms, Thrombosis	Prescription Medicine	Global	Controlled Release Formulation
	Gastin®CR Tab.	Mosapride 15mg	Gastrointestinal symptoms	Prescription Medicine	Global	Fixed Dose Combination
	Omethyl Cutilet® Soft capsule	Omega-3 acid ethylester 90 2g	Hypertriglyceridemia	Prescription Medicine	Global	New fixed dose
Kuhnil Pharm	Rogumega®	Omega3+ Rosuvastatin	Hyperlipidemia	Prescription drug	Italy	
	Rosumega®	Omega3+ Rosuvastatin	Hyperlipidemia	Prescription drug	Mongolia	
	Omacomini Soft Cap.	omega-3	Hyperlipidemia	Prescription drug	Global	
	Pulmican	Budesonide	Asthma	Prescription drug	Mongolia	
	Aventro	Ipratropium	COPD	Prescription drug	Mongolia	
Medytox	Neuronox, Meditoxin, Siax etc.	Clostridium botulinum toxin typeA (Hall strain)	1. Blepharospasm 2. Equinus foot deformity 3. Glabellar lines 4. Upper limb spasticity 5. Lateral canthal lines(crow's feet lines) 6. Cervical dystonia	Biologics	Global	
	Coretox	Clostridium botulinum toxin typeA (150kDa) (Hall strain)	1. Glabella lines 2. Upper limb spasticity	Biologics	Global	
	Neurakin	Ibuprofen piconol	1. acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea-like dermatitis, perioral dermatitis 2. herpes zoster 3. acne vulgaris	Generic drugs	Global	
	Levocontra	Levonorgestrel	Emergency contraceptive	Generic drugs	Global	
Samjin Pharm. Co., Ltd.	PLATLESS Tablet	Clopidogrel Bisulfate	Antithrombotic	Prescription Medicine	Global	
	Neurocava PG Capsule	Pregabalin	Anticonvulsants	Prescription Medicine	Global	
	Intrack Tablet	Carvedilol	Hypertension	Prescription Medicine	Global	
	Ferbon Injection	Folate Calcium	Detoxifying agents	Prescription Medicine	Global	
	Clopidogrel Bisulfate	APIs	Antithrombotic	Active Pharmaceutical Ingredient	Global	
	Rosuvastatin Calcium	APIs	HMG-CoA reductase inhibitor	Active Pharmaceutical Ingredient	Global	
Samyang Biopharmaceuticals Corporation	Genexol® PM	Paclitaxel	Breast cancer, NSCLC, Ovarian cancer	Injection	South East Asia, India	
	Nanoxel® M	Docetaxel	Breast cancer, NSCLC, Esophageal cancer, H&N cancer, Ovarian cancer, Gastric cancer, Prostate cancer		-	
	Genexol®	Paclitaxel	Ovarian cancer, Breast cancer, NSCLC, Gastric cancer		Europe, South East Asia, CIS	
	Docetaxel	Docetaxel	Breast cancer, NSCLC, Esophageal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate cancer		Europe, CIS	
	Nexatin®	Oxaliplatin	Colorectal cancer, Gastric cancer		Europe, Japan, CIS	
	Crabcitabine®	Gemcitabine	Pancreas cancer, NSCLC, Ovarian cancer, Breast cancer, Bladder cancer, Biliary tract cancer		-	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
Samyang Biopharmaceuticals Corporation	Pemed® S	Pemetrexed	NSCLC, Mesothelioma	Injection	-	
	Azolid®	Azacitidine	MDS, AML, CMML		CIS	
	Decilid®	Decitabine	MDS, AML		-	
	Protezomib®	Bortezomib	MCL, MM		-	
	Bendalid®	Bendamustine	MM		-	
	Lenalid®	Lenalidomide	MM		CIS	
	Everose™	Everolimus	Breast cancer, Renal cancer, Pancreatic Neuroendocrine tumor, GI and Lung Neuroendocrine tumor, TSC-Renal Angiomyolipoma, TSC-SEGA	Tablet	-	
	Palonosetron	Palonosetron	Anti-emetics	Injection	-	
	Zolenic®	Zoledronic Acid	Hypercalcemia of malignancy, Bone metastasis		CIS	
	Rheumastop®	Diclofenac	Rheumatoid arthritis	Plaster	-	
	Nicostop®	Nicotine	Smoking cessation	Patch, Gum	-	
	Fentaderm®	Fentanyl	Chronic pain	Patch	-	
	Demecure®	Rivastigmine	Dementia		-	
	Tulobuterol	Tulobuterol	Bronchial asthma		-	
	Angiderm®	Nitroglycerin	Angina		-	
		Paclitaxel	Ovarian cancer, Breast cancer, NSCLC, Gastric cancer	API	USA, Europe, Japan, South East Asia, India, North America	
	Docetaxel	Breast cancer, NSCLC, Esophageal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate cancer	Europe, Japan, Middle East			
	Pemetrexed	NSCLC, Mesothelioma	Middle East			
	Bortezomib	MCL, MM	Middle East			
	Cabazitaxel	Prostate cancer	-			
Shin Poong Pharm. Co.,Ltd	Pyramax® Tablet	Pyronaridine & Artesunate	Anti-malarial	Prescription Medicine	Global	
	Pyramax® Granule	Pyronaridine & Artesunate	Anti-malarial (Pediatric formulation)	Prescription Medicine	Global	
	CandeAmlo® Tablet	Amlodipine & Candesartan	Hypertension	Prescription Medicine	Global	
	EzeRosu® Tablet	Rosuvastatin & Ezetimibe	Hyperlipidemia	Prescription Medicine	Global	
	Medicurtain®	Sodium hyaluronate & hydroxyethylstarch	Anti-adhesion (Surgery)	Prescription Medicine	Global	
SK Chemicals Co., Ltd.	Rivastigmine patch	rivastigmine	Symptomatic therapy for alzheimer Dementia or Parkinson's disease Dementia	Patch	Europe, Columbia, New zealand etc. (19 centuries)	
Taejoon Pharmaceutical Co., Ltd.	Cyporin N	Cyclosporine	Dry eye	Prescription medicine	EU, Asia	
	Xalost Preservative Free	Latanoprost	Anti-glaucoma	Prescription medicine	US, EU, Asia	
	Xalost Plus	Latanoprost plus Timolol maleate	Anti-glaucoma	Prescription medicine	EU, Asia	
	Xalost	Latanoprost	Anti-glaucoma	Prescription medicine	EU, Asia	
	Gadobrix	Gadobtrol	MRI contrast enhancement	Prescription medicine	US, EU, Asia	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
Tego Science	Kaloderm®	Allogeneic Keratinocytes	- Deep 2 nd degree burn over 30% of TBSA - 3 rd degree burn over 10% of TBSA	Cell Therapy Product (Prescription Medicine)	Global	
	Rosmir®	Autologous Fibroblasts	Improvement of Nasojugal Grooves	Cell Therapy Product (Prescription Medicine)	Global	
	Neoderm®	Reconstituted 3D Human Skin	For cosmetics testing and drug discovery	Tester Kit for Research	Global	Alternative methods to animal testing
Yuhan Corporation	Pregabalin SR Tablet	Pregabalin	Neuropathic pain	ETC Medicine	Asia, Middle East, North Africa, CIS, Latin America, etc.	
	Duowell Tablet	Telmisartan, Rosuvastatin	Treatment for hypertension and hyperlipidemia	ETC Medicine		
	Rosuampine Tablet	Amlodipine, Rosuvastatin	Treatment for hypertension and hyperlipidemia	ETC Medicine		
	Rosumet SR Tablet	Metformin SR, Rosuvastatin	Antidiabetic	ETC Medicine		
	Newfactan	Bovine Lung Surfactant	Treatment for respiratory distress syndrome of newborns	ETC Medicine		
	Yucla Tablet	Amoxicillin, Clavulanate Potassium	Antibiotics	ETC Medicine		
	Almagate Suspension	Almagate	Antiacidic functions	OTC Medicine		
	Antiplamine S Lotion	Methyl Salicylate, L-menthol	Anti-inflammatory agent	OTC Medicine		
	Willogel Double Action Suspension	Sodium alginate, Calcium carbonate, Sodium bicarbonate	Alleviation of heartburn and indigest	OTC Medicine		
	Nazacare Nasal Spray Solution	Momethasone Furoate	Nasal symptoms of allergic rhinitis, Nasal polyps, Acute rhinosinusitis	ETC Medicine		
Cough-S Syrup	Ammonium Chloride, Chlorpheniramine Maleate, Dextromethorphan Hydrobromide Hydrate, DL-Methylephedrine Hydrochloride	Cough, Sputum	ETC Medicine			
Yungjin Pharm. Co.,Ltd.	CEROCAPENE (API, tab., fine gran.)	Cefcapene Pivoxil	Antibiotics	ETC Medicine	Worldwide	
	CEFDITOREN (API, tab., fine gran.)	Cefditoren Pivoxil	Antibiotics	ETC Medicine	Worldwide	
	CEFMETAZOLE (API, inj.)	Cefmetazole Sodium	Antibiotics	ETC Medicine	Worldwide	
	CEFOTIAM (API)	Cefotiam HCl/HCl+Na2CO3	Antibiotics	ETC Medicine	Worldwide	
	CEFTRIAXONE (inj.)	Ceftriaxone Sodium	Antibiotics	ETC Medicine	Worldwide	
	CEFTAZIDIME (inj.)	Ceftazidime Hydrate	Antibiotics	ETC Medicine	Worldwide	
	CEFOXETIL (API, tab., DS)	Cefpodixime Proxetil	Antibiotics	ETC Medicine	Worldwide	
	CEROFAZIL (tab., DS)	Cefprozil Hydrate	Antibiotics	ETC Medicine	Worldwide	

Company	Product name	Active Ingredient	Indication	Category	Expected country	Note
Yungjin Pharm. Co.,Ltd.	CEFDINIR (API, tab., fine gran.)	Cefdinir Hydrate	Antibiotics	ETC Medicine	Worldwide	
	CANDESARTAN (API, tab.)	Candesartan Cilexetil	Cardiovascular	ETC Medicine	Worldwide	
	LOXOPROFEN (API)	Loxoprofen Sodium	NSAID	ETC Medicine	Worldwide	
	FEBUXOSTAT (API)	Febuxostat	Antihyperuricemic	ETC Medicine	Worldwide	
	LINEZOLIN (tab.)	Linezolid	Antibiotics	ETC Medicine	Worldwide	
	YUNGPENEM (inj.)	Imipenem, Cilastatin	Antibiotics	ETC Medicine	Worldwide	
	BAROSCON DOUBLE ACTION (susp.)	Sodium alginate, calcium carbonate, sodium bicarbonate	Anti-GERD	OTC Medicine	Worldwide	
	Pediatric Complete Multivitamin (syr.)	Multivitamins	Supplement	OTC Medicine	Worldwide	

2. Technology Transfer

Worldwide

Company	Category	Indication	Development Status		Targeted country	Note
			Korea	Overseas		
ABLBio, Inc.	A bispecific angiogenesis inhibition	Gastric, colorectal, ovarian cancer/AMD	Phase 1a Preparation for Phase 1b/2a		Global except Korea -Worldwide except Korea and Japan	
	2 bispecific antibody candidates of angiogenesis inhibition, 1 antibody candidate of tumor associated bispecific antibody candidates of T cell engager	Solid and blood cancer	Nonclinical		Global except Korea (1 T cell engager: worldwide and China except other Asian countries)	
	2 bispecific antibody candidates of T-cell engager	Solid and blood cancer	Nonclinical		Global	
	2 bispecific antibody candidates of T-cell engager	Solid and blood cancer	Nonclinical		Global	
	1 bispecific antibody candidate of T-cell engager	Blood cancer	Nonclinical		Asia except China	
	ABL201 (ADC, Antibody-Drug Conjugates)	Blood cancer	Nonclinical		Global	
Alteogen, Inc.	ALT-B4	Cancer	0	0	Worldwide	
	ALT-P1	Growth hormone deficiency	2	1	Worldwide	
	ALT-P7	Breast cancer	1	0	Worldwide	
	ALT-L9	wAMD	1	0	Worldwide	
	ALT-LS2	Breast cancer	0	0	Worldwide	
BCWORLD PHARM. CO., LTD.	BCWP_Y001	Anti-Cancer	-	-	Global	
	BCWP_Y002	Anti-fungal	-	-	Global	
	BCWP_Y007	Antibiotics	-	-	Global	
Boryung Pharmaceutical co.,Ltd.	New Chemical Entity (ARB: Fimasartan)	Hypertension	Launching	Launching	CHINA, BRAZIL, MENA	
	Oncology	Antineoplastic	Launching	Launching	MENA, LATAM, ASIA, CIS	
	New Chemical Entity (H2RA: lafutidine)	Gastric ulcer	Launching		Global	
Chong Kun Dang pharmaceutical Corp.	CKD-504 (Small Molecule)	Parkinson's Disease	Non-clinical	-	Worldwide	
	CKD-506 (Small Molecule)	Autoimmune Disease	-	Phase 1 (Netherland)	Worldwide	
	CKD-516 (Small Molecule)	Colon Cancer	Phase 1/2a		Worldwide	
	CKD-519 (Small Molecule)	Dyslipidemia	-	Phase 1/2a Australia)	Worldwide	
	CKD-581 (Small-Molecule)	Multiple myeloma	Phase 1/2a	-	Worldwide	
	CKD-701 (ranibizumab biosimilar candidate)	AMD, DME	Non-clinical	-	Worldwide	
	CKD-11101 (Darbepoetin- alfa biosimilar candidate)	Anemia	Phase 3	-	Worldwide	
	Methoxy Polyethylene Glycol-Epoetin Beta biosimilar candidate	Anemia	Process development	-	Worldwide	
	CKD-760 (Adalimumab) biosimilar candidate	Rheumatoid Arthritis	Non-clinical	-	Worldwide	
	CKD-12101 (Pegfilgrastim) biosimilar candidate	Leukopenia	Non-clinical	-	Japan	
	Hyaluronic acid (cell bank & manufacturing technology)	Process development			ROW & China	
	Botulinum toxin (cell bank & manufacturing technology)	Process development			ROW & China	
	HPV vaccine (cell bank & manufacturing technology)	Process development			ROW & China	

Company	Category	Indication	Development Status		Targeted country	Note
			Korea	Overseas		
Corestem Inc.	Neuronata-R®	Amyotrophic lateral sclerosis (ALS)	Phase III approved	Phase III Scheduled	Korea, United States (Global)	
	CS20AT04	systemic lupus erythematosus	Phase 1 Completed	-		
Crystal-Genomics, Inc.	Ivaltinostat	Pancreatic cancer, Myelodysplastic syndromes	Phase II		Global	
	CG-650	Acute/Chronic pain	Phase I		Global	
	CG-651	Neuropathic pain	Phase I		Global	
	CG-549	ABSSSI, Osteomyelitis and other serious S. aureus infections including MRSA		Phase I	Global	
	CG-598	Inflammatory bowel disease	Preclinical		Global	
Daewoong Pharmaceutical	DWN12088	IPF		Phase 1, AU TGA	Global	
	DWP17061	OA pain			Global	PC
	DWP212525	Autoimmune disease			Global	PC
	DWP213388	Autoimmune disease			Global	PC
Dong-A ST	DA-1241 (GPR119 agonist)	Type 2 diabetes		IND approved (US)	US/EU	
	DA-8010 (M3 receptor antagonist)	Overactive Bladder		Ph I on-going (EU)	US/EU	
	DA-3880 (Darbepoetin alfa, Aranesp® biosimilar)	Anemia		Ph I completed (EU) Global Ph III planned, Ph I completed (JP), Ph III on-going (JP)	US/EU	
	DA-9801 (Botanical drug)	Diabetic Neuropathy		Ph II completed (US), Ph III planned (US)	US/EU	
	DMB-3111 (Trastuzumab, Herceptin® biosimilar)	Breast cancer		Ph I completed (JP), Ph III planned (EU)	US/China/MENA	
Genexine, Inc.	GX-I7 (Long-acting IL-7)	Solid tumor	Phase 1b	Phase 1	Global	
		Glioblastoma	Phase 1b/2a	Phase 1b/2a	Global	
		TNBC (in comb. with Keytruda)	Phase 1b/2	Phase 1b/2	Global	
		Skin cancer (in comb. with Tecentrig)	-	Phase 1b/2a	Global	
	GX-188 (HPV DNA therapeutic vaccine)	Cervical Cancer (in comb. with Keytruda)	Phase 1b/2a	-	Global	
	GX-H9 (Long-acting hGH)	AGHD & PGHD	Completed Phase 2	Completed Phase 2	Global	
	GX-G3 (Long-acting G-CSF)	Neutropenia	-	Completed Phase 2	Global	
	GX-E4 (Long-acting EPO)	CKD-induced Anemia	Phase 3 IND Approval	Phase 3 IND Approval	Global	
	GX-G6 (Long-acting GLP-1)	Type 2 Diabetes	-	Phase 2 IND Approval	Global	
	GX-G8 (Long-acting GLP-2)	Short Bowel Syndrome	-	Phase 1 IND Approval	Global	
	GX-P1 (Long-acting PD-L1)	Autoimmune diseases Organ transplantation	-	Phase 1 IND Approval	Global	

Company	Category	Indication	Development Status		Targeted country	Note
			Korea	Overseas		
Handok Inc.	Biologics	Adult growth hormone deficiency (AGHD)	Ph 2 completed	Ph 2 completed	USA/EU	
	Biologics	Pediatric growth hormone deficiency (PGHD)	Phase 2	Phase 2	USA/EU	
HANLIM PHARM. CO., LTD.	Herb	Acute bronchitis	NDA		Japan, EU, South-East Asia	
	Small molecule	AMD		EU Phase II	USA, EU	
	Small molecule	Rheumatoid arthritis	Phase II		USA, EU	
	Small molecule	Liver transplantation	Phase I		USA, EU	
	Stem cell	Systemic lupus erythematosus	Phase I		Japan, USA, EU	
	IMD	Mixed hyperlipidemia	Marketed		Japan, South-East Asia	
	IMD	Allergic rhinitis, Pruritus	Marketed		Japan, South-East Asia	
	IMD	Breast lesion surgery marker	Phase III		USA, EU	
Hanmi Pharm. Co., Ltd.	Efpeglenatide (^{LAPS} GLP-1; long-acting GLP-1 analog)	Diabetes		Phase III	Global	Licensed to Sanofi
	HM12460A/HM12470 (^{LAPS} Insulin/ ^{LAPS} Insulin 115; long-acting Insulin analog)	Diabetes		Phase I	Global	
	HM14220 (^{LAPS} Insulin/ ^{LAPS} GLP-1 Combination)	Diabetes	Preclinical		Global	Licensed to Sanofi
	HM12525A (^{LAPS} GLP/GCG; long-acting GLP/GCG)	Obesity		Phase II	Global	
	Efpegsomatropin (^{LAPS} hGH; long-acting hGH)	GHD	Phase II	Phase II	Global	
	Rolontis™ (eflapegrastim; ^{LAPS} GCSF; long-acting GCSF analog)	Neutropenia		Filed	Global	WW rights ex. Korea, China and Japan licensed to Spectrum Pharmaceuticals
	HM15211 (^{LAPS} GLP/GIP/GCG; long-acting GLP/GIP/GCG)	NASH		Phase I	Global	
	HM15136 (^{LAPS} Glucagon; long-acting glucagon analog)	Obesity & Cogenital Hyperinsulinism	Phase I	Phase I	Global	
	HM15450 (^{LAPS} ASB; long-acting enzyme replacement therapy)	Mucopolysaccharidosis	Pre-clinical		Global	
	HM15912 (^{LAPS} GLP-2; long-acting GLP-2 analog)	Short bowel syndrome	Phase I		Global	
	Oraxol™ (Paclitaxel + HM30181A)	Breast cancer		Phase III	Global	WW rights ex. Korea licensed to Athenex
	Oratecan™ (Irinotecan + HM30181A)	Solid tumors		Phase II	Global	WW rights ex. Korea licensed to Athenex
	Poziotinib (pan-HER inhibitor)	Breast, Lung cancer		Phase II	Global	WW rights ex. Korea, China licensed to Spectrum Pharmaceuticals
	HM95573 (pan RAF inhibitor)	Solid tumors	Phase I		Global	WW rights ex. Korea licensed to Genentech
	HM71224 (BTK inhibitor)	Autoimmune disease		Phase II	Global	

Company	Category	Indication	Development Status		Targeted country	Note
			Korea	Overseas		
Hanmi Pharm. Co., Ltd.	HM43239 (FLT3 inhibitor)	Acute Myeloid Leukemia	Phase I	Phase I	Global	
	LSD1 inhibitor	Small Cell Lung Cancer	Pre-clinical		Global	
	IBI315/BH2950	Solid tumors		Phase I	Global	Partnership with Innovent to co-develop a novel immuno-oncology bispecific antibody
HK inno.N Corporation	K-CAB Tab. (Tegoprazan)	Gastroesophageal reflux disease (GERD)	Launched	Phase 1 (Completed)	Global	NCE
	IN-B001	Prevention of Hand, Foot & Mouth Disease	In progress Phase I	-		Vaccine
	IN-A002	Rheumatoid Arthritis	Pre-clinical	-		NCE
HUONS CO., LTD.	Drug	Dry eye syndrome	Phase II IND submission	Preclinical completed	Global	
	Drug	Dry eye syndrome	Launched		Global	
Hyundai Pharm Co., Ltd	HD-6277	Diabetes	-	Phase 1 completed (EU EMA)	Global	
	BPDO-1603	Alzheimer's disease	Phase 3	-	Global	
	HDDO-1728	Alzheimer's disease	Formulation	-	Global	
	HDDO-1756	Hyperlipidemia	Formulation	-	Global	
	HDDO-1801	Respiratory disease	Phase 1	-	Global	
ILDONG Pharmaceutical Co., Ltd.	Ophthalmology	Age-related Macular Degeneration (AMD)	Preclinical		Global	
	Anti-cancer / CNS	Chronic Lymphocytic Leukemia (CLL) / Relapsing form of Multiple Sclerosis (RMS)	-	P3 / P2	Southeast Asia	
ISU Abxis	ISU104	ErbB3 positive cancers (head and neck, etc.)	Phase 1		Global	
	ISU305	Paroxysmal Nocturnal Hemoglobinuria		Phase 1 (Australia/New Zealand)	Global	
	ISU106	Various cancers	Non-clinical		Global	
	Abcertin®	Gaucher's Disease		Phase 1 (Australia)	Global	
	Fabagal®	Fabry's Disease	Phase 3	Preparing Phase 3	Global	
JW Pharmaceutical Corporation	CWP232291	Acute Myeloid Leukemia, Multiple Myeloma, Gastric Cancer	Phase 1b (ongoing)	-	Global	
	URC102	Gout	Phase 2b (ongoing)	-	Global except China	
	CWL080061	Alopecia	-	-	Global	
	CreaVax-HCC	Hepato Cellular Carcinoma	Phase 3 (ongoing)	-	Global	
Korea United Pharm. Inc.	Clavixin® Duo Capsule	Acute coronary syndrome (antiplatelet)	Launched		Global	
	Kalomin® Tab.	Upper respiratory tract infections	Launched		Global	
	Losasc® Tab 5/50	Hypertension	Launched		Global	
	Levotics® CR	Upper, chronic respiratory tract infections	Launched		Global	
	Unigril® CR	Antithrombotic	Launched		Global	
	Glicetile® syrup	Degenerative brain syndromes	Launched		Global	
	Fenorics® EH Tab	Hyperlipidemia	Launched		Global	

Company	Category	Indication	Development Status		Targeted country	Note
			Korea	Overseas		
LG Chemical, Ltd.	LR19074	Gout	N/A	in Phase 2 (US)	Global	
	LR19019	Ulcerative colitis	N/A	in Phase 2 (US)	Global	
	LR19021	Obesity	N/A	Preclinical	Global	
Medytox Inc.	MT912	Macular Degeneration	TBD	TBD	Global	Biobetter
	MT927	Immune Disorder	TBD	TBD	Global	Immune cell therapeutics
	MT971	Inflammatory Bowel Disease	TBD	TBD	Global	Live Biotherapeutic Product
	MT981	Solid cancers	TBD	TBD	Global	Antibody New Drug
	MT921	Fat Reduction	Phase 2 clinical trial in progress	TBD	Global	New Chemical Entity
Pharmicell Co., Ltd.	Cellgram-AMI	Acute Myocardial Infarction	Launched	-	Global	-
Samjin Pharm. Co., Ltd.	SA001 (Rebamipide mofetil)	Dry eye syndrome, Sjogren syndrome	Clinical II	Pre-clinical	Global	
	SJP1803/1804 (NOX inhibitor, APX-1004F)	Macular degeneration	Pre-clinical	Pre-clinical	Global	Eye drop, Implant for long-term delivery
	SJP1604 (APTA-DC, APTA-16)	Cancer (Resistant AML/MDS)	Pre-clinical	-	-	
	SJP1602 (FAK/Pyk2 dual inhibitor)	Cancer (TNBC, solid tumor)	Pre-clinical	Pre-clinical	Global	
Samyang Biopharmaceuticals Corporation	POLYMER-BASED PARENTERAL DDS TECH.	Renal cell carcinoma	Preclinical	-	US, EU	Solubility enhancing
	POLYMER-BASED PARENTERAL DDS TECH.	Cancer	Ph 1	-	US, EU	Solubility enhancing, Sustained release
	Absorption enhancing oral DDS Tech.	Emesis	Preclinical	-	US, EU	Bioavailability enhancing tablet
	Fast dissolving oral DDS Tech.	Allergy, Emesis	Ph 1 (BEQ completed)	-	US, EU	Fast dissolving tablet
	Colon specific oral DDS Tech.	IBD, IBS	Preclinical (completed)	-	US, EU	Colon specific delivery system
	Oncolytic virus, nucleic acid delivery Tech.	Cancer	Preclinical	Preclinical	US, EU	Stability enhanced nano shells
Shin Poong Pharm. Co., Ltd.	Otaplimastat (SP-8203)	Acute Ischemic Stroke	Phase 2b On-going	-	Global	Combination with tPA, the SOC
	SP-8008	Anti-platelet	-	Phase 1 On-going	Global	Oral, less bleeding
	SP-8356	Cerebro-cardiovascular diseases	-	Preclinical Completed	Global	Oral, enhanced vessel elasticity
	SP5M001	Osteoarthritis	Phase 1/2 On-going	-	Global	Long-lasting viscosupplement
	SP-8416	Heart failure	Lead optimization	-	Global	-
Tego Science	Rosmir®	Improvement of Nasojugal Grooves	Phase II completed & Marketing approved		Global	

Company	Category	Indication	Development Status		Targeted country	Note
			Korea	Overseas		
Yungjin Pharm. Co.,Ltd.	YPL-001 (Botanical)	Respiratory(COPD)	-	Phase 2	Global	
	KL1333 (NCE)	Metabolic (Mitochondrial disease)	-	Phase 1	Japan	Licensed out to NeuroVive, ODD approval (US FDA)
	YRA-1909 (Botanical)	Immunology (Rheumatoid arthritis)	Phase 2	-	Korea	
	YPN-005 (NCE)	Oncology (HCC, TNBC, AML, etc)	Preclinical	-	Global	

3. Certifications from Health Authorities

Company	Product name	Active Ingredient	dosage form	Indication	International certification	Note
Boryong Pharmaceutical co.,Ltd.	Cefon Inj.	Cefoperazone, Sulbactam	FP	Antibiotics	PMDA	
	Fosomycin Inj.	Fosfomycin	FP	Antibiotics	PMDA	
	Roxithromycin Tab.	Roxithromycin	FP	Antibiotics	PMDA	
	Gelfos	ALPO 4	FP	Gastrointestinal	Taiwan FDA	
	Kanarb	Fimasartan	API	Cardiovascular	EU GMP	scheduled
	Neoplatin Inj.	Carboplatin	FP	Antineoplastic	EU GMP	scheduled
	Alacepril	Alacepril	API	Cardiovascular	PMDA	
	Pitavastatin	Pitavastatin	API	Cardiovascular	PMDA	
	Fexofenadine	Fexofenadine	API	Antihistamine	PMDA	
	Aripiprazole	Aripiprazole	API	Schizophrenia	PMDA	
	Montelukast	Montelukast	API	Respiratory	PMDA	
Tamsulosin	Tamsulosin	API	Urology System	PMDA		
Celltrion	Remsima	Infliximab	SC	Rheumatoid Arthritis	EMA Approval (2019. 11.)	
	Remsima	Infliximab	IV	Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohn's Disease, Psoriasis	EMA Approval (2013. 09.) FDA Approval (2016. 04.)	
	Truxima	Rituximab	IV	Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis	EMA Approval (2017. 02.) FDA Approval (2018. 11.)	
	Herzuma	Trastuzumab	IV	HER2-Positive Metastatic Breast Cancer, Early Breast Cancer, Metastatic Gastric Cancer	EMA Approval (2018. 02.) FDA Approval (2019. 05.)	
CKD Pharmaceutical Corp.	Tacrolimus Cap.	Tacrolimus 0.5, 1, 5mg	Cap.	Immunosuppressant	GMP	Japan/MHLW
	Ceftriazone sodium inj.	Ceftriaxone sodium 0.5, 1mg	Inj.	Antibiotics	GMP	Japan/MHLW
	Cefazolin sodium inj.	Cefazolin sodium 0.5, 1, 2mg	Inj.	Antibiotics	GMP	Japan/MHLW
	Pengood	Bacampicillin hydrochloride	Tab.	Antibiotics	GMP	Japan/MHLW
	Plant certification (Sterile/Non-sterile drug)				GMP	Japan/MHLW
	Plant certification (Tablet/Capsule manufacturing line)				GMP	Sudan/ National Medicines and Poisons Board
	Plant certification (Solid drug /Anticancer drug manufacturing line)				GMP	Thailand/ Thailand Food and Drug Administration
	Plant certification (Sterile/Non-sterile drug)				GMP	Kazakhstan/ Ministry of Health, Republic of Kazakhstan
	plant certification (Biologic drug)		Capsule.	Immunosuppressant	GMP	Japan/NHLW

Company	Product name	Active Ingredient	dosage form	Indication	International certification	Note
DAE HWA PHARMACEUTICAL CO., LTD.	Plocfen cataplasma	Flurbiprofen	Cataplasma	Muscular pain	cGMP	
	On-Q plaster	Methyl salicylate Diphenhydramine dl-camphor l-menthol Mentha oil Tocopherol acetate Vanilyl nonylamide	Plaster	Muscular pain	cGMP	
	Almetamin Tab.	Betamethasone Dexchlorpheniramine maleate	Tablet	Acute urticaria and others	Ethiopia	
	Kebanon plaster	Ketoprofen	Plaster	Muscular pain	Philippines	
	Top-roll soft capsule	Ginseng powder and others	Soft capsule	Tonics and nutritional supplementation	Qatar	
Daewoong Pharmaceutical	Nabota	Botulinum toxin Type A	Injection	Treatment of wrinkles between the eyebrows	cGMP, EU-GMP, Canada GMP	
	Ursa	Ursodeoxycholic acid	Tablet, Capsule	Cholestasis (including PBC, PSC), viral hepatitis C, gallstone	PIC/S GMP	
	Olostar	Olmesartan/Rosuvastatin	Tablet	Concomitant hypertension and dyslipidemia	PIC/S GMP	
	Luphere	Leuprorelin Acetate	Depot Injection	Prostate cancer, endometriosis, uterine fibroid, postmenopausal breast cancer, central precocious puberty	PIC/S GMP	
	Easyef	Recombinant human Epidermal Growth Factor	Solution	Diabetic foot ulcer	PIC/S GMP	
	Caretropin	Recombinant human growth hormone	PFS	Growth hormone deficiency and Turner syndrome	PIC/S GMP	
	Eposis	Recombinant human Erythropoietin α	PFS	Anemia in end stage renal disease (ESRD)	PIC/S GMP	
Handok Inc.	Amaryl M SR 2/500mg	Glimepiride Metformin	Solid dosage form	Type II diabetes	Jordan MOH Ukraine- PIC/S Peru Authority	
	Amaryl M IR 2/500mg	Glimepiride Metformin	Solid dosage form	Type II diabetes	Russian MOH Oman MOH Taiwan FDA -PIC/S Ukraine- PIC/S Peru Authority Saudi Arabia FDA	
	AMARYL M 2mg/500mg film coated tablets	Glimepiride Metformin	Solid dosage form	Type II diabetes	Brazil Authority (ANVIS) Colombia FDA	
	Esperson oint. 0.25%	Desoxymethasone Semi-solid	Semi-solid dosage form	Corticosteroid-responsive dermatoses	Taiwan FDA -PIC/S	
	Daonil tab.	Glibenclamide	-	Type II diabetes		
	Lasix tab.	Furosemide	-	Edema., Hypertensionos		
	Frisium tab. 10mg	Clobazam	-	Epilepsy		
KETOTOP Plaster	Ketoprofen	Plaster	Degenerative arthritis (Osteoarthritis), Periarthritis, humeral epicondylitis (tennis elbow etc.), Peritendinitis, tendovaginitis, myalgia, post-traumatic swelling/pain	Singapore Malaysia Kazakhstan		
Hanmi Pharm. Co.,Ltd	Gugu	Tadalafil	Tab.	Erectile Dysfunction	PMDA (Japan)	
	Lozap AM	Amlodipine + Losartan	Tab,	Hypertension	Russia GMP	
	Hyalrheuma	Hyaluronic acid	Inj,	Osteoarthritis	US FDA(cGMP)	
		Esomeprazole	API	GI	US FDA(cGMP)	
		Cefotaxime	API	Antibiotics	EU GMP	

Company	Product name	Active Ingredient	dosage form	Indication	International certification	Note
Hanmi Pharm. Co.,Ltd		Cefotaxime	API	Antibiotics	EU GMP	
		Ceftazidime	API	Antibiotics	EU GMP	
		Ceftizoxime	API	Antibiotics	PMDA (Japan)	
		Raloxifene	API	Osteoporosis	PMDA (Japan)	
		Losartan	API	CV	PMDA (Japan)	
HK inno.N Corporation	Best-Call®	Cefmenoxime Hcl	Inj.	Infection	Japan GMP Inspection	Supply APIs to a Japanese Company
	First-Sin®	Cefozopran Hcl	Inj.	Infection	Japan GMP Inspection	
	Pan-Sprorin®	Cefotiam Hcl	Inj.	Infection	Japan GMP Inspection	
	Banan® tab.	Cefopodoxime	Tab.	Infection	Japan GMP Inspection	Supply bulk-products to a Japanese company
	Banan® dry syrup	Cefopodoxime	Syrup	Infection	Japan GMP Inspection	
	Ceftazidime inj.	Ceftazidime	Inj.	Infection	Japan DMF	
	Ceftriaxone inj.	Ceftriaxone	Inj.	Infection	Japan DMF	
HUONS CO., LTD.	Sodium Chloride Inj. 0.9%	Sodium Chloride	Ampoule	Diluent for injectable drug	US – FDA cGMP	
	Lidocaine HCl Inj. 1%	Lidocaine HCl	Ampoule	Local Anesthesia	Lidocaine HCl	
	Bupivacaine HCl in 8.25% Dextrose Inj. 0.75%	Bupivacaine HCl	Ampoule	Local Anesthesia	US – FDA cGMP	
	Epilido Inj.	Lidocaine, Adrenaline	Cartridge Ampoule	Dental Anesthesia	Japan - PMDA	
	Isotonic Sodium Chloride Solution	Sodium Chloride	BFS 20mL	Flushing compatible intravenous tubing system and in dwelling intravascular access devices	Japan - PMDA	
	20% Glucose for Inj.	Glucose	BFS 20mL	Hypokalemia, cardiac collapse, glucose supplement during hypoglycemia, Cerebral edema, Shock, Cardiac disease, Non-oral supplement of water, Diagnosis	Japan - PMDA	
	Norepirin Inj.	Norepinephrine Bitartrate	Ampoule	Treatment of heart failure	KSA – SFDA Philippines – FDA Philippines	
	Hyaclon Inj.	Sodium Hyaluronate	Prefilled Syringe	Treatment of Osteoarthritis	EU - Ministry of Health of the Republic of Poland	
ILDONG Pharmaceutical Co., Ltd	Biovita	Probiotics & Vitamin	Granule	Probiotic Digestion and Vitamin Supplement for babies	USA	
	Xelobig	Capecitabine	Tablet	Breast cancer, colon cancer, rectal cancer	PAKISTAN, MYANMAR	
	Algik	Pemetrexed	Injection	Pleural mesothelioma, Non-small cell lung cancer	PAKISTAN	
	Vicure	Entecavir	Tablet	Hepatitis B virus (HBV) infection	AZERBAIJAN, PERU, MONGOLIA, HONG KONG	
	Memanto	Mematine	Tablet	Moderate-to-severe Alzheimer's disease	PHILIPPINES, MYANMAR	
ILDONG Pharmaceutical Co., Ltd	N/A	Fursultiamine HCl	API	Vitamins	JAPAN	
	N/A	Topiramate	API	Anticonvulsant drug material	JAPAN	

Company	Product name	Active Ingredient	dosage form	Indication	International certification	Note
ISU Abxis	Abcertin®	Imiglucerase	Injection	Gaucher's Disease	Iran GMP Iran MOHME	2014 2015
	Abcertin®	Imiglucerase	Injection	Gaucher's Disease	Mexico GMP Mexico MOH	2014 2015
	Abcertin®	Imiglucerase	Injection	Gaucher's Disease	Russian GMP	2019
JW Pharmaceutical Corporation	Prepenem Inj.	Imipenem monohydrate and Cilastatin sodium	Injection	Antibiotics	PMDA	
	Pospenem Inj.	Meropenem trihydrate	Injection	Antibiotics	ANVISA	
	Itraconazole SD	Itraconazole	Solid Dispersion	Fungal Infection	PMDA	
	Toracona tab	Itraconazole	Tablets	Fungal Infection	PMDA	
	Imipenem Mixture	Imipenem monohydrate and Cilastatin sodium	API	Antibiotics	PMDA COFEPRIS	
	Meropenem Mixture	Meropenem trihydrate	API	Antibiotics	PMDA COFEPRIS	
	Montelukast tab.	Montelukast sodium	Tablets	asthma symptoms and to relieve the symptoms of seasonal allergies	PMDA	
	Bosentan tab.	Bosentan	API	Treating high blood pressure in the lungs	PMDA	
Korea Otsuka Pharm- aceutical	Cilostazol	Cilostazol			FDA, PMDA	USA, Japan
	Abilify OD, Abilify OS	Aripiprazole	Tab, OS	Schizophrenia	MHRA, ANSM	UK, France
	Mucosta	Rebamipide	Tab	Gastritis	DRAP, NPCB	Pakistan, Malaysia
	Pletaal	Cilostazol	Tab	cerebral infarction	NPCB	Malaysia
	Rebamipide	Rebamipide			PMDA	Japan
	Samsca	Tolvaptan	Tab	hyponatremia, ADPKD	BPOM	Indonesia
	Abilify OD	Aripiprazole	Tab	Schizophrenia	TFDA	Tiwan
Kuhnle Pharm	Rogumega®	Omega3+ Rosuvastatin	Capsule	Hyperlipidemia	EU GMP	
	Rogumega®	Omega3+ Rosuvastatin	Capsule	Hyperlipidemia	Marketing Authorization (Netherlands, Italy)	
Medytox Inc.	Neuronox, Meditoxin, Siax etc.	Clostridium botulinum toxin typeA (Hall strain)	Biopharm- aceutical products (Injection)	1. Blepharospasm 2. Equinus foot deformity 3. Glabellar lines 4. Upper limb spasticity 5. Lateral canthal lines (crow's feet lines) 6. Cervical dystonia	GMP	Brazil, Colombia, Iran, Saudi Arabia etc.
Samyang Biopharm- aceuticals Corporation	Oxaliplatin Inj.	Oxaliplatin API	Injection	Anti-cancer	Japan(PMDA) GMP	2019
	Paclitaxel Inj. Docetaxel Inj. Pemetrexed Inj. Oxaliplatin Inj. Azacitidine Inj.	Paclitaxel API Docetaxel API Pemetrexed API Oxaliplatin API Azacitidine API	Injection	Anti-cancer	EU(Germany) GMP	2019
	Paclitaxel API Docetaxel API	Paclitaxel Docetaxel	API	Anti-cancer	Japan(PMDA) GMP	2015
	Paclitaxel API Docetaxel API Synthetic paclitaxel API Pemetrexed API	Paclitaxel Docetaxel Synthetic Paclitaxel Pemetrexed	API	Anti-cancer	EU(Germany) GMP	2014
	Diclofenac Patch	Diclofenac diethylammonium	Plaster	NSAIDs	Australia(TGA) GMP	2010

Company	Product name	Active Ingredient	dosage form	Indication	International certification	Note
Shin Poong Pharm. Co.,Ltd	Pyramax® Tab.	Pyronaridine, artesunate	Tablet	Anti-malarial	EU GMP Certification	-
	Pyramax® Gran.	Pyronaridine, artesunate	Granules	Anti-malarial (Pediatric formulation)	EU GMP Certification	-
	Medicurtain®	Sodium hyaluronate, hydroxyethyl starch	Injection	Anti-adhesion (Surgery)	CE Certification	-
	-	Clopidogrel bisulfate	API	Anti-platelet	PMDA	-
	-	Loxoprofen sodium	API	NSAID	PMDA	-
	-	Telmisartan	API	Hypertension	PMDA	-
	-	Sulbactam sodium	API	Anti-biotic	PMDA	-
	-	Valsartan	API	Hypertension	PMDA	-
	-	Irbesartan	API	Hypertension	PMDA	-
	-	Fosfomycin sodium	API	Anti-biotic	PMDA	-
-	Cilostazol	API	Antithrombotic	PMDA	-	
SK Chemicals Co., Ltd.	OMED	omeprazole	Tablet	Gastric Ulcer	EU GMP	
	Wondron Patch	rivastigmine	Patch	Alzheimer Dementia	EU GMP	
Taejoon Pharmaceutical Co., Ltd.	Xalost Plus	Latanoprost plus Timolol maleate	Solution	Anti-glaucoma	EU GMP certification	
	Xalost	Latanoprost	Solution	Anti-glaucoma	EU GMP, ANVISA, NAFDAC certification	
Tego Science	Holoderm®	Autologous Keratinocytes	-Deep 2 nd degree burn over 30% of TBSA	Cell Therapy Product (Prescription Medicine)	GMP	
	Kaloderm®	Allogeneic Keratinocytes	-3 rd degree burn over 10% of TBSA	Cell Therapy Product (Prescription Medicine)	GMP	
	Rosmir®	Autologous Fibroblasts	Improvement of Nasojugal Grooves	Cell Therapy Product (Prescription Medicine)	GMP	
Yuhan Corporation	API1	API1	-	Antiviral	USFDA, TGA, PMDA	
	API2	API2	-	Antiviral	USFDA, TGA, PMDA	
	API3	API3	-	Antiviral	USFDA, TGA, PMDA	
	API4	API4	-	Antiviral	USFDA	
	API5	API5	-	Antiviral	USFDA	
	API6	API6	-	Antiviral	USFDA	
	PMH	PMH	-	Antibiotic	USFDA, TGA, EDQM	
	Voglibose	Voglibose	-	Antiplatelet	PMDA	
	Cilostazol	Cilostazol	-	Antiplatelet	PMDA	
Levofloxacin	Levofloxacin	-	Antibiotic	PMDA		
Yungjin Pharm. Co.,Ltd.	Cefaclor	Cefaclor Monohydrate	Capsule	Antibiotics	PMDA	
	Cefmetazole	Cefmetazole Sodium	API	Antibiotics	PMDA	
	Cefotiam	Cefotiam HCl	API	Antibiotics	PMDA	
	Cefdinir	Cefdinir	API, Tab.	Antibiotics	PMDA	
	Cefditoren	Cefditoren Pivoxil	API, Fine Granule	Antibiotics	PMDA	
	Ceftriaxone	Ceftriaxone Sodium	Inj.	Antibiotics	PMDA	
	Cefcapene	Cefcapene Pivoxil HCl	API, Tablet, Fine Granule	Antibiotics	PMDA	
	Caftazidime	Caftazidime Pnetahydrate	API, Injection	Antibiotics	PMDA	
	Cefpodoxime	Cefpodoxime Proxetil	API, Tablet, Dry Syrup	Antibiotics	PMDA	
	Candesartan	Candesartan Cilexetil	API	Cardiovascular Agents	PMDA	
	Loxoprofen	Loxoprofen Sodium	API	Antipyretics and analgesics, anti-inflammatory agents	PMDA	